Cover
Cover - shares | 6 Months Ended | |
Jun. 30, 2022 | Aug. 14, 2022 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Document Period End Date | Jun. 30, 2022 | |
Document Fiscal Period Focus | Q2 | |
Document Fiscal Year Focus | 2022 | |
Current Fiscal Year End Date | --12-31 | |
Entity File Number | 000-13789 | |
Entity Registrant Name | ADHERA THERAPEUTICS, INC. | |
Entity Central Index Key | 0000737207 | |
Entity Tax Identification Number | 11-2658569 | |
Entity Incorporation, State or Country Code | DE | |
Entity Address, Address Line One | 8000 Innovation Parkway | |
Entity Address, City or Town | Baton Rouge | |
Entity Address, State or Province | LA | |
Entity Address, Postal Zip Code | 70820 | |
City Area Code | (919) | |
Local Phone Number | 518-3748 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 63,127,450 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 |
Current assets | ||
Cash | $ 849 | $ 76 |
Prepaid expenses | 127 | 120 |
Total current assets | 976 | 196 |
Total assets | 976 | 196 |
Current liabilities | ||
Accounts payable | 2,339 | 2,309 |
Due to related parties | 46 | 46 |
Accrued expenses | 3,697 | 3,110 |
Accrued dividends | 445 | 5,477 |
Term loans | 6,307 | 5,677 |
Convertible notes payable, net | 1,039 | 986 |
Derivative liability | 7,098 | 7,697 |
Total current liabilities | 20,971 | 25,302 |
Total liabilities | 20,971 | 25,302 |
Commitments and contingencies (Note 9) | ||
Stockholders’ deficit | ||
Preferred stock | ||
Common stock, $0.006 par value; 180,000,000 shares authorized, 63,127,450 and 16,998,836 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively | 379 | 102 |
Additional paid-in capital | 33,186 | 27,809 |
Accumulated deficit | (53,558) | (53,017) |
Treasury stock (119,541 shares) | (2) | |
Total stockholders’ deficit | (19,995) | (25,106) |
Total liabilities and stockholders’ deficit | 976 | 196 |
Series C Convertiable Preferred Stock [Member] | ||
Stockholders’ deficit | ||
Preferred stock | ||
Series D Convertiable Preferred Stock [Member] | ||
Stockholders’ deficit | ||
Preferred stock | ||
Series E Convertiable Preferred Stock [Member] | ||
Stockholders’ deficit | ||
Preferred stock | ||
Series F Convertiable Preferred Stock [Member] | ||
Stockholders’ deficit | ||
Preferred stock | ||
Series G Convertiable Preferred Stock [Member] | ||
Stockholders’ deficit | ||
Preferred stock |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 |
Preferred stock, par value | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized | 100,000 | 100,000 |
Common stock, par value | $ 0.006 | $ 0.006 |
Common stock, shares authorized | 180,000,000 | 180,000,000 |
Common stock, shares issued | 63,127,450 | 16,998,836 |
Common stock, shares outstanding | 63,127,450 | 16,998,836 |
Treasury stock, shares | 119,541 | 119,541 |
Series C Convertible Preferred Stock [Member] | ||
Preferred stock, par value | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized | 1,200 | 1,200 |
Preferred stock, shares issued | 100 | 100 |
Preferred stock, shares outstanding | 100 | 100 |
Preferred stock, liquidation preference value | $ 510,000 | $ 510,000 |
Series D Convertible Preferred Stock [Member] | ||
Preferred stock, par value | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized | 220 | 220 |
Preferred stock, shares issued | 40 | 40 |
Preferred stock, shares outstanding | 40 | 40 |
Preferred stock, liquidation preference value | $ 12,000 | $ 12,000 |
Series E Convertible Preferred Stock [Member] | ||
Preferred stock, par value | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized | 3,500 | 3,500 |
Preferred stock, shares issued | 267 | 267 |
Preferred stock, shares outstanding | 267 | 267 |
Preferred stock, liquidation preference value | $ 1,799,614 | $ 1,799,614 |
Series F Convertible Preferred Stock [Member] | ||
Preferred stock, par value | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized | 2,200 | 2,200 |
Preferred stock, shares issued | 0 | 358 |
Preferred stock, shares outstanding | 0 | 358 |
Series G Convertible Preferred Stock [Member] | ||
Preferred stock, par value | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized | 6,000 | 6,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Preferred stock, liquidation preference value | $ 5,000 | $ 5,000 |
Consolidated Statements of Oper
Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Operating expenses | ||||
Sales and marketing | $ 8 | $ 17 | ||
General and administrative | 449 | 121 | 709 | 222 |
Total operating expenses | 449 | 129 | 709 | 239 |
Loss from operations | (449) | (129) | (709) | (239) |
Other income (expense) | ||||
Interest expense | (361) | (248) | (672) | (491) |
Initial and change in the fair value of derivative liability | 1,012 | (87) | 1,679 | (87) |
Gain on extinguishment of debt | 210 | 215 | ||
Amortization of debt discount | (313) | (50) | (488) | (125) |
Total other income (expense) | 548 | (385) | 734 | (703) |
Net income (loss) | 99 | (514) | 25 | (942) |
Accrued and deemed dividends | (406) | (392) | (566) | (1,274) |
Net Loss Applicable to Common Stockholders | $ (307) | $ (906) | $ (541) | $ (2,216) |
Net loss per share – Common Stockholders - basic and diluted | $ (0.01) | $ (0.08) | $ (0.01) | $ (0.20) |
Weighted average shares outstanding - basic and diluted | 22,801,669 | 11,669,779 | 40,078,424 | 11,270,044 |
Consolidated Statements of Stoc
Consolidated Statements of Stockholders' Deficit - USD ($) $ in Thousands | Preferred Stock [Member] Series C Preferred Stock [Member] | Preferred Stock [Member] Series D Preferred Stock [Member] | Preferred Stock [Member] Series E Preferred Stock [Member] | Preferred Stock [Member] Series F Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Treasury Stock [Member] | Total |
Beginning balance, value at Dec. 31, 2020 | $ 67 | $ 29,772 | $ (44,612) | $ (14,773) | |||||
Balance, shares at Dec. 31, 2020 | 100 | 40 | 3,458 | 361 | 11,112,709 | ||||
Accrued dividend | 505 | (882) | (377) | ||||||
Issuance of common stock with term loan | $ 3 | 23 | 26 | ||||||
Issuance of common stock with term loan, shares | 518,000 | ||||||||
Issuance of warrants with convertible notes | 28 | 28 | |||||||
Beneficial conversion feature convertible notes | 19 | 19 | |||||||
Net income (loss) | (428) | (428) | |||||||
Ending balance, value at Mar. 31, 2021 | $ 70 | 30,347 | (45,922) | (15,505) | |||||
Balance, shares at Mar. 31, 2021 | 100 | 40 | 3,458 | 361 | 11,630,709 | ||||
Beginning balance, value at Dec. 31, 2020 | $ 67 | 29,772 | (44,612) | (14,773) | |||||
Balance, shares at Dec. 31, 2020 | 100 | 40 | 3,458 | 361 | 11,112,709 | ||||
Net income (loss) | (942) | ||||||||
Conversion of Series E Preferred to common stock | 1 | ||||||||
Ending balance, value at Jun. 30, 2021 | $ 71 | 30,417 | (46,828) | (16,340) | |||||
Balance, shares at Jun. 30, 2021 | 100 | 40 | 3,450 | 361 | 11,785,290 | ||||
Beginning balance, value at Mar. 31, 2021 | $ 70 | 30,347 | (45,922) | (15,505) | |||||
Balance, shares at Mar. 31, 2021 | 100 | 40 | 3,458 | 361 | 11,630,709 | ||||
Issuance of warrants with convertible notes | 69 | 69 | |||||||
Net income (loss) | (514) | (514) | |||||||
Accrued and deemed dividend | 11 | (392) | (381) | ||||||
Issuance of common stock for cashless exercise of warrants | |||||||||
Issuance of common stock for cashless exercise of warrants, shares | 53,571 | ||||||||
Issuance of common stock for Series E conversion | $ 1 | 9 | 10 | ||||||
Issuance of common stock for Series E conversion, shares | (8) | 101,010 | |||||||
Ending balance, value at Jun. 30, 2021 | $ 71 | 30,417 | (46,828) | (16,340) | |||||
Balance, shares at Jun. 30, 2021 | 100 | 40 | 3,450 | 361 | 11,785,290 | ||||
Beginning balance, value at Dec. 31, 2021 | $ 102 | 27,809 | (53,017) | (25,106) | |||||
Balance, shares at Dec. 31, 2021 | 100 | 40 | 3,326 | 358 | 16,988,836 | ||||
Accrued dividend | (364) | (364) | |||||||
Issuance of common stock with term loan | $ 2 | 26 | 28 | ||||||
Issuance of common stock with term loan, shares | 254,401 | ||||||||
Net income (loss) | (74) | (74) | |||||||
Issuance of common stock with convertible notes | $ 1 | 17 | 18 | ||||||
Issuance of common stock with convertible notes, shares | 250,000 | ||||||||
Ending balance, value at Mar. 31, 2022 | $ 105 | 27,852 | (53,455) | (25,498) | |||||
Balance, shares at Mar. 31, 2022 | 100 | 40 | 3,326 | 358 | 17,493,237 | ||||
Beginning balance, value at Dec. 31, 2021 | $ 102 | 27,809 | (53,017) | $ (25,106) | |||||
Balance, shares at Dec. 31, 2021 | 100 | 40 | 3,326 | 358 | 16,988,836 | ||||
Issuance of common stock with term loan, shares | 2,665,672 | ||||||||
Net income (loss) | $ 25 | ||||||||
Conversion of Series E Preferred to common stock | 5,056 | ||||||||
Ending balance, value at Jun. 30, 2022 | $ 379 | 33,186 | (53,558) | (2) | (19,995) | ||||
Balance, shares at Jun. 30, 2022 | 100 | 40 | 267 | 63,127,450 | |||||
Beginning balance, value at Mar. 31, 2022 | $ 105 | 27,852 | (53,455) | (25,498) | |||||
Balance, shares at Mar. 31, 2022 | 100 | 40 | 3,326 | 358 | 17,493,237 | ||||
Accrued dividend | (202) | (202) | |||||||
Issuance of common stock with term loan | $ 2 | 9 | 11 | ||||||
Issuance of common stock with term loan, shares | 384,615 | ||||||||
Net income (loss) | 99 | 99 | |||||||
Conversion of Series E Preferred to common stock | $ 244 | 4,812 | 5,056 | ||||||
Conversion of Series E Preferred to common stock, shares | (3,059) | 40,706,120 | |||||||
Conversion of Series F Preferred to common stock | $ 28 | 513 | 541 | ||||||
Conversion of Series F Preferred to common stock, shares | (358) | 4,662,524 | |||||||
Repurchase of common stock | (2) | (2) | |||||||
Repurchase of common stock, shares | (119,046) | ||||||||
Ending balance, value at Jun. 30, 2022 | $ 379 | $ 33,186 | $ (53,558) | $ (2) | $ (19,995) | ||||
Balance, shares at Jun. 30, 2022 | 100 | 40 | 267 | 63,127,450 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||
Jun. 30, 2022 | Mar. 31, 2022 | Jun. 30, 2021 | Mar. 31, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | |
Cash Flows Used in Operating Activities: | |||||||
Net income (loss) | $ 99,000 | $ (74,000) | $ (514,000) | $ (428,000) | $ 25,000 | $ (942,000) | |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
Amortization of debt discount and fees | 488,000 | 129,000 | |||||
Accrued interest expense | 672,000 | 487,000 | |||||
Derivative income (expense) | (1,679,000) | 87,000 | |||||
Gain on debt extinguishment | (210,000) | (215,000) | |||||
Changes in operating assets and liabilities: | |||||||
Prepaid expenses | (7,000) | ||||||
Accounts payable | 30,000 | 23,000 | |||||
Accrued expenses | (4,000) | 98,000 | |||||
Net Cash Used in Operating Activities | (690,000) | (118,000) | |||||
Cash Flows Provided by Financing Activities: | |||||||
Proceeds from notes payable and convertible notes, net of original issue discounts | 2,200,000 | 171,000 | |||||
Notes payable and convertible notes issuance costs | (328,000) | (12,000) | |||||
Repurchase of common stock | (2,000) | ||||||
Repayment of principal and interest on notes payable | (407,000) | ||||||
Net Cash Provided by Financing Activities | 1,463,000 | 159,000 | |||||
Net increase in cash | 773,000 | 41,000 | |||||
Cash – Beginning of Year | $ 76,000 | $ 1,000 | 76,000 | 1,000 | $ 1,000 | ||
Cash - End of Year | 849,000 | $ 42,000 | 849,000 | 42,000 | $ 76,000 | ||
Supplementary Cash Flow Information: | |||||||
Cash paid for interest | 81,000 | ||||||
Cash paid for taxes | |||||||
Non-cash Investing and Financing Activities: | |||||||
Conversion of Series E Preferred stock to common stock | $ 5,056,000 | 5,056,000 | 1,000 | ||||
Conversion of Series F Preferred stock to common stock | 541,000 | ||||||
Debt discounts for issuance costs, warrants and derivatives | (10,000) | (97,000) | |||||
Issuance of common stock for conversion of convertible notes | 28,000 | 26,000 | |||||
Issuance of common stock with convertible notes | 20,000 | 26,000 | |||||
Cashless exercise of warrants | 4,000 | ||||||
Accrued and deemed dividends | $ 566,000 | $ 1,274,000 |
Organization and Business Opera
Organization and Business Operations | 6 Months Ended |
Jun. 30, 2022 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization and Business Operations | Note 1 – Organization and Business Operations Adhera Therapeutics, Inc. and its wholly-owned subsidiaries, MDRNA Research, Inc. (“MDRNA”), Cequent Pharmaceuticals, Inc. (“Cequent”), Atossa Healthcare, Inc. (“Atossa”), and IThenaPharma, Inc. (“IThena”) (collectively “Adhera,” or the “Company”), is an emerging specialty biotech company that, to the extent that resources and opportunities become available, is strategically evaluating its focus including a return to a drug discovery and development company. On July 28, 2021, we as licensee and Melior Pharmaceuticals II, LLC (“Melior II”) entered into an exclusive license agreement for the development, commercialization and exclusive license of MLR-1019. MLR-1019 is being developed as a new class of therapeutic for Parkinson’s disease (PD) and is, to the best of our knowledge, the only drug candidate today to address both movement and non-movement aspects of PD. Under the Agreement, we were granted an exclusive license to use the Melior II Patents and know-how to develop products in consideration for cash payments upon meeting certain performance milestones as well as a royalty of 5% of gross sales. On August 20, 2021, we as licensee entered into an exclusive license agreement with Melior Pharmaceuticals I, Inc. (“Melior I”) for the development, commercialization and exclusive license of MLR-1023. MLR-1023 is being developed as a novel therapeutic for Type 1 diabetes. On October 20, 2021, we as licensee expanded the exclusive licensing agreement with Melior I to include two additional clinical indications for Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation. To the extent that resources have been available, the Company has continued to work with its advisors in an effort to restructure our company and to identify potential strategic transactions to enhance the value of our company as such opportunities arise, including potential transactions and capital raising initiatives involving the assets relating to our legacy RNA interference programs, as well as business combination transactions with operating companies. There can be no assurance that the Company will be successful at identifying any such transactions, that it will continue to have sufficient resources to actively attempt to identify such transactions, or that such transactions will be available upon terms acceptable to us or at all. If the Company does not complete any significant strategic transactions, or raise substantial additional capital, in the near future, it is likely that the Company will discontinue all operations and seek bankruptcy protection. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2022 (Unaudited) |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2022 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | Note 2 – Summary of Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”) for complete financial statements. This quarterly report should be read in conjunction with the consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The information furnished in this Report reflects all adjustments (consisting of normal recurring adjustments), which are, in the opinion of management, necessary for a fair presentation of our financial position, results of operations and cash flows for each period presented. The results of operations for the six months ended June 30, 2022, are not necessarily indicative of the results for the year ending December 31, 2022 or for any future period. Principles of Consolidation The consolidated financial statements include the accounts of Adhera Therapeutics, Inc. and the wholly-owned subsidiaries, Ithena, Cequent, MDRNA, and Atossa, and eliminate any inter-company balances and transactions. All wholly-owned subsidiaries of Adhera Therapeutics, Inc. are inactive. Going Concern and Management’s Liquidity Plans The accompanying consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. As of June 30, 2022, the Company had cash and cash equivalents of approximately $ 849,000 20.0 The Company has incurred recurring losses and negative cash flows from operations since inception and has funded its operating losses through the sale of common stock, preferred stock, warrants to purchase common stock, convertible notes and secured promissory notes. The Company recognized net income of approximately $ 25,000 690,000 53.6 In addition, to the extent that the Company continues its business operations, the Company anticipates that it will continue to have negative cash flows from operations, at least into the near future. However, the Company cannot be certain that it will be able to obtain such funds required for its our operations at terms acceptable to the Company or at all. General market conditions, as well as market conditions for companies in the Company’s financial and business position, as well as the ongoing issues arising from the COVID-19 pandemic, the Ukraine war and inflation and the Federal Reserve interest rate increases in response, may make it difficult for the Company to seek financing from the capital markets, and the terms of any financing may adversely affect the holdings or the rights of its stockholders. If the Company is unable to obtain additional financing in the future, there may be a negative impact on the financial viability of the Company. The Company plans to increase working capital by managing its cash flows and expenses, divesting development assets and raising additional capital through private or public equity or debt financing. There can be no assurance that such financing or partnerships will be available on terms which are favorable to the Company or at all. While management of the Company believes that it has a plan to fund ongoing operations, there is no assurance that its plan will be successfully implemented. Failure to raise additional capital through one or more financings, divesting development assets or reducing discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance date of this Report. The consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties. Summary of Significant Accounting Policies Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of six months or less at the time of purchase to be cash equivalents. As of June 30, 2022, the Company had approximately $ 849,000 The Company deposits its cash with major financial institutions that may at times exceed the federally insured limit. As of June 30, 2022 the Company had $ 599,000 250,000 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2022 (Unaudited) Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include accruals related to our operating activity including legal and other consulting expenses, the fair value of non-cash equity-based issuances, the fair value of derivative liabilities, and the valuation allowance on deferred tax assets. Actual results could differ materially from such estimates under different assumptions or circumstances. Fair Value of Financial Instruments The Company considers the fair value of cash, accounts payable, debt, and accrued expenses not to be materially different from their carrying value. These financial instruments have short-term maturities. We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (“FASB”) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into six broad levels. The following is a brief description of those six levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. As of June 30, 2022, the Company measured conversion features on outstanding convertible notes and warrants as a derivative liability using significant unobservable prices that are based on little or no verifiable market data, which is Level 3 in the fair value hierarchy, resulting in a fair value estimate of approximately $ 7.1 2.80 3.01 206.01 317.47 1.07 no Schedule of Fair Value Measurements (in thousands) (Level 1) (Level 2) (Level 3) Total Fair Value Measurements at June 30, 2022 Quoted Other Significant (in thousands) (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 7,098 $ 7,098 Total $ - $ - $ 7,098 $ 7,098 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2022 (Unaudited) A roll forward of the level 3 valuation financial instruments is as follows: Schedule of Roll Forward of Level 3 Financial Instruments (In thousands) Warrants Notes Total Six-Months Ended June 30, 2022 (In thousands) Warrants Notes Total Balance at December 31, 2021 $ 5,336 $ 2,361 $ 7,697 Initial valuation of derivative liabilities included in debt discount 1,151 163 1,314 Initial valuation of derivative liabilities included in derivative expense — 108 108 Reclassification of derivative liabilities loss to gain on debt extinguishment — (233 ) (233 ) Change in fair value included in derivative expense (617 ) (1,171 ) (1,788 ) Balance at June 30, 2022 $ 5,870 $ 1,228 $ 7,098 ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding equity instruments. Convertible Debt and Warrant Accounting Debt with warrants In accordance with ASC Topic 470-20-25, when the Company issues debt with warrants, the Company treats the relative fair value of the warrants as a debt discount, recorded as a contra-liability against the debt, and amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations. The offset to the contra-liability is recorded as additional paid in capital in the Company’s consolidated balance sheets if the warrants are not treated as a derivative. The Company determines the fair value of the warrants using the Black-Scholes Option Pricing Model (“Black-Scholes”), the binomial model or the Monte Carlo Method based upon the underlying conversion features of the debt and then computes and records the relative fair value as a debt discount. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations. Convertible debt – derivative treatment When the Company issues debt with a conversion feature, it first assesses whether the conversion feature meets the requirements to be accounted for as stock settled debt. If it does not meet those requirements then it is assessed on whether the conversion feature should be bifurcated and treated as a derivative liability, as follows: a) one or more underlyings, typically the price of our common stock; b) one or more notional amounts or payment provisions or both, generally the number of shares upon conversion; c) no initial net investment, which typically excludes the amount borrowed; and d) net settlement provisions, which in the case of convertible debt generally means the stock received upon conversion can be readily sold for cash. An embedded equity-linked component that meets the definition of a derivative does not have to be separated from the host instrument if the component qualifies for the scope exception for certain contracts involving an issuer’s own equity. The scope exception applies if the contract is both a) indexed to its own stock; and b) classified in stockholders’ equity in its statement of financial position. Convertible debt – beneficial conversion feature Prior to the Company’s adoption of ASU No. 2020-06, Debt—Debt with Conversion and Other Options Derivatives and Hedging—Contracts in Entity’s Own Equity Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2022 (Unaudited) If the conversion feature does not qualify for derivative treatment, the convertible debt is treated as traditional debt. Recently Issued Accounting Pronouncements Recently Adopted In January 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-04, Intangibles-Goodwill and Other (Topic 350) (“ASU 2017-04”), which will simplify the goodwill impairment calculation by eliminating Step 2 from the current goodwill impairment test. The new standard does not change how a goodwill impairment is identified. The Company will continue to perform its quantitative goodwill impairment test by comparing the fair value of its reporting unit to its carrying amount, but if the Company is required to recognize a goodwill impairment charge, under the new standard, the amount of the charge will be calculated by subtracting the reporting unit’s fair value from its carrying amount. Under the current standard, if the Company is required to recognize a goodwill impairment charge, Step 2 requires it to calculate the implied value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination and the amount of the charge is calculated by subtracting the reporting unit’s implied fair value of goodwill from the goodwill carrying amount. The standard was effective January 1, 2020. The adoption of ASU 2017-04 did not have a material impact on the Company’s historical consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which will simplify the accounting for certain financial instruments with characteristics of liabilities and equity, including certain convertible instruments and contracts on an entity’s own equity. Specifically, the new standard will remove the separation models required for convertible debt with cash conversion features and convertible instruments with beneficial conversion features. It will also remove certain settlement conditions that are currently required for equity contracts to qualify for the derivative scope exception and will simplify the diluted earnings per share calculation for convertible instruments. ASU 2020-06 will be effective January 1, 2022, for the Company and may be applied using a full or modified retrospective approach. Early adoption is permitted, but no earlier than January 1, 2021, for the Company. The Company adopted ASU No. 2020-06 on January 1, 2021. Management determined such adoption did not have a material impact on the overall stockholders’ equity (deficit) in the Company’s consolidated financial statements. In May 2021, FASB issued ASU 2021-04: Earnings Per Share (Topic 260), Debt— Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40), to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in ASU 2021-04 provide the following guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic: 1. An entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as an exchange of the original instrument for a new instrument. 2. An entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as follows: a. For a modification or an exchange that is a part of or directly related to a modification or an exchange of an existing debt instrument or line-of-credit or revolving-debt arrangements (hereinafter, referred to as a “debt” or “debt instrument”), as the difference between the fair value of the modified or exchanged written call option and the fair value of that written call option immediately before it is modified or exchanged. Specifically, an entity should consider: i. An increase or a decrease in the fair value of the modified or exchanged written call option in applying the 10 percent cash flow test and/or calculating the fees between debtor and creditor in accordance with Subtopic 470-50, Debt—Modifications and Extinguishments. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2022 (Unaudited) ii. An increase (but not a decrease) in the fair value of the modified or exchanged written call option in calculating the third-party costs in accordance with Subtopic 470-50. b. For all other modifications or exchanges, as the excess, if any, of the fair value of the modified or exchanged written call option over the fair value of that written call option immediately before it is modified or exchanged. 3. An entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange on the basis of the substance of the transaction, in the same manner as if cash had been paid as consideration, as follows: a. A financing transaction to raise equity. The effect should be recognized as an equity issuance cost in accordance with the guidance in Topic 340, Other Assets and Deferred Costs. b. A financing transaction to raise or modify debt. The effect should be recognized as a cost in accordance with the guidance in Topic 470, Debt, and Topic 835, Interest. c. Other modifications or exchanges that are not related to financings or compensation for goods or services or other exchange transactions within the scope of another Topic. The effect should be recognized as a dividend. For entities that present EPS in accordance with Topic 260, that dividend should be an adjustment to net income (or net loss) in the basic EPS calculation. An entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option to compensate for goods or services in accordance with the guidance in Topic 718, Compensation—Stock Compensation. In a multiple-element transaction (for example, one that includes both debt financing and equity financing), the total effect of the modification should be allocated to the respective elements in the transaction. The amendments in ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt the amendments in ASU 2021-04 in an interim period, the guidance should be applied as of the beginning of the fiscal year. The adoption by the Company as of January 1, 2022 did not have a significant impact on its financial statements. Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures. Net Loss per Common Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. Potentially dilutive securities which include outstanding warrants, stock options, convertible notes and preferred stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. For all periods presented, basic and diluted net loss were the same. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2022 (Unaudited) The following table presents the computation of net loss per share (in thousands), except share and per share data): Schedule of Earnings Per Share, Basic and Diluted Three Months Ended Six Months Ended 2022 2021 2022 2021 Numerator Net income (loss) $ 99 $ (514 ) $ 25 $ (942 ) Accrued and deemed dividends (406 ) (392 ) (566 ) (1,274 ) Net Loss allocable to common stockholders $ (307 ) $ (906 ) $ (541 ) $ (2,216 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic and diluted 22,801,669 11,669,779 40,078,424 11,270,044 Net loss per share of common stock, basic and diluted Net loss per share $ (0.01 ) $ (0.08 ) $ (0.01 ) $ (0.20 ) The following number of shares have been excluded from diluted net (loss) since such inclusion would be anti-dilutive: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Six-Months Ended June 30, 2022 2021 Stock options outstanding 380,000 387,550 Convertible notes 48,802,730 20,952,683 Warrants 102,655,674 59,836,767 Series C Preferred Stock 66,667 66,667 Series D Preferred Stock 50,000 50,000 Series E Preferred Stock 3,559,229 43,325700 Series F Preferred Stock — 4,446,980 Total 155,514,300 129,066,417 As of June 30, 2022, the Company’s fully diluted common stock and equivalents exceeded the 180,000,000 Stock-Based Compensation The Company applies the provisions of ASC 718, Compensation—Stock Compensation (“ASC 718”) For stock options issued, the Company estimates the grant date fair value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised if and when a forfeiture becomes probable. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2022 (Unaudited) Income Taxes Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss and credit carry forwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. |
Prepaid Expenses
Prepaid Expenses | 6 Months Ended |
Jun. 30, 2022 | |
Prepaid Expenses | |
Prepaid Expenses | Note 3 – Prepaid Expenses As of June 30, 2022, and December 31, 2021 prepaid expenses were approximately $ 127,000 120,000 |
Notes Payable and Convertible P
Notes Payable and Convertible Promissory Notes | 6 Months Ended |
Jun. 30, 2022 | |
Debt Disclosure [Abstract] | |
Notes Payable and Convertible Promissory Notes | Note 4 – Notes Payable and Convertible Promissory Notes The following table summarizes the Company’s outstanding term loans: Schedule of Outstanding Term Loans (in thousands) June 30, 2022 December 30, 2021 2019 Term Loan $ 5,677 $ 5,677 2022 Term Loan 2,222 - Notes payable 7,899 5,677 Unamortized discounts (1,592 ) - Loans payable $ 6,307 $ 5,677 2019 Term Loans During 2019, the Company entered into term loan subscription agreements with certain accredited investors, pursuant to which the Company issued secured promissory notes in the aggregate principal amount of approximately $ 5.7 707,000 The promissory notes accrued interest at a rate of 12 15 The unpaid principal balance of the notes, plus accrued and unpaid interest thereon, matured on June 28, 2020 On June 26, 2021, the holders of the 2019 Term Loans agreed to subordinate their lien and security interest in the assets of the Company and its subsidiaries as set forth in the Security Agreement dated June 28, 2019 to the holders of the June 2021 convertible notes. On April 19, 2022, a majority of the noteholders of the secured non-convertible promissory notes of the Company issued between June 18, 2019, and August 5, 2019 which matured on August 5, 2020 consented to forbear collection efforts until September 30, 2022. Accordingly, the collateral agent for the note holders in consideration of the signed noteholder agreements agreed to forbear all notes outstanding. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2022 (Unaudited) The Company recognized approximately $ 212,000 422,000 As of June 30, 2022, the Company had approximately $ 2.4 5.7 2.4 2022 Term Loan On May 11, 2022, the Company entered into a Securities Purchase Agreement with investors whereby the Company issued the Purchasers Original Issue Discount Promissory Notes in the aggregate principal amount of $ 2,222,222 222,222 2,000,000 22,222,218 1,692,200 307,800 The Notes are due on the earliest to occur of (i) the 12 month anniversary of the original issuance date of the Notes, or May 11, 2023, (ii) a financing transaction which results in the Company’s common stock being listed on a national securities exchange, and (iii) an event of default. If an event of default occurs before the Company’s common stock is listed on a national securities exchange, the event of default would require a repayment of 125% of the outstanding principal, accrued interest and other amounts owing thereon unless the Company is trading on a national securities exchange in which case the repayment would be 100%. The Notes bear interest at 8% per annum, subject to an increase to 15% in case of an event of default as provided for therein. In addition, at any time before the 12-month anniversary of the date of issuance of the Notes, the Company may, upon five days’ prior written notice to the Purchaser, prepay all of the then outstanding principal amount of the Notes for cash in an amount equal to the sum of 105% of all amounts due and owing hereunder, including all accrued and unpaid interest The Warrants are exercisable for a 66 November 11, 2027 0.04 The Company recorded a total debt discount of $ 1,693.000 including an original issue discount of $ 222,222 , a discount related to issuance costs of $ 307,800 , a discount related to the issuance of common stock of $ 11,820 1,151,000 The Company’s obligations under the Notes are secured by a first priority lien on all of the assets of the Company and its wholly-owned subsidiaries pursuant to a Security Agreement, dated May 11, 2022 and among the Company, its wholly-owned subsidiaries, the Purchasers, and the lead investor as the collateral agent. For the three and six months ended June 30, 2022, the Company recognized approximately $ 100,640 25,100 At June 30, 2022, the Company has recorded $ 2,222,222 25,100 1,592,000 Convertible Promissory Notes The following table summarizes the Company’s outstanding convertible notes as of June 30, 2022, and December 31, 2021: Schedule of Convertible Promissory Notes (in thousands) June 30, 2022 December 31, 2021 Convertible Notes $ 1,431 $ 1,516 Unamortized discounts and fees (392 ) (530 ) Convertible notes payable, net $ 1,039 $ 986 Ten convertible notes with outstanding principal of approximately $ 1.2 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2022 (Unaudited) Secured Convertible Promissory Note – February 2020 On February 5, 2020, the Company entered into a Securities Purchase Agreement with accredited investors and issued the investors, (i) original issue discount Convertible Promissory Notes with a principal of $ 550,500 10 499,950 The Convertible Notes matured on August 5, 2020 10 18 Until the Convertible Notes are no longer outstanding, the Convertible Notes are convertible, in whole or in part, at any time, and from time to time, into shares of Common Stock at the option of the noteholder. The conversion price is the lower of: (i) $ 0.50 70 60 0.05 The exercise price of the Warrants shall be equal to the conversion price of the Convertible Notes, provided, that on the date that the Convertible Notes are no longer outstanding, the exercise price shall be fixed at the conversion price of the Convertible Notes on such date, with the exercise price of the Warrants thereafter (and the number of shares of Common Stock issuable upon the exercise thereof) being subject to adjustment as set forth in the Warrants. The warrants have a 5 The Company recorded a discount related to the Warrants of approximately $ 322,000 30,000 53,000 21,000 38,000 381,000 On March 19, 2021, the holder of the Convertible Note converted $ 25,900 518,000 On July 29, 2021, the holder of the Convertible Note converted $ 27,500 550,000 On August 16, 2021, the holder of the Convertible Note converted $ 25,000 500,000 On September 13, 2021, the holder of the Convertible Note converted $ 32,500 650,000 On October 4, 2021, the holder of the Convertible Note converted $ 26,250 525,000 On November 29, 2021, the holder of the Convertible Note converted $ 31,150 623,012 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2022 (Unaudited) The total note principal and interest converted during the year ended December 31, 2021, was $ 168,300 3,366,012 554,000 386,000 245,000 245,000 141,000 On January 27, 2022, the conversion price of the notes and warrants was adjusted to be the lower of (x) 60 0.039 For the three and six months ended June 30, 2022, the Company recognized approximately $ 21,000 46,000 25,000 50,000 As of June 30, 2022, the Company had accrued interest on the February 2020 Convertible Note of approximately $ 147,000 As of June 30, 2022, the Company remains in default on the repayment of remaining principal of $ 457,359 140 The 40% premium will be recorded once a demand occurs Secured Convertible Promissory Note – June 2020 On June 26, 2020, the Company issued to an existing investor in the Company a 10 58,055 52,500 5,555 December 26, 2020 10 14,000 18 The Note is convertible, in whole or in part, into shares of common stock of the Company at the option of the noteholder at a conversion price of $ 0.02 65 50,000 203,000 The obligations of the Company under the Note are secured by a senior lien and security interest in all of the assets of the Company and certain of its wholly-owned subsidiaries pursuant to the terms and conditions of a Security Agreement dated June 26, 2020 by the Company in favor of the noteholder. In connection with the issuance of the Note, the holders of the secured promissory notes that the Company issued to select accredited investors between June 28, 2019 and August 5, 2019 in the aggregate principal amount of approximately $ 5.7 On January 27, 2022, the conversion price of the note was adjusted to the lower of 65 0.039 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2022 (Unaudited) For the three six-month period ended June 30, 2022 and June 30, 2021 the Company recognized approximately $ 2,600 and $ 5,300 in interest related to the note. As of June 30, 2022, the debt discount and issuance costs for the note were fully amortized. As of June 30, 2022, the Company remains in default on the repayment of principal of $ 58,055 21,000 140 The 40% premium will be recorded once a demand occurs Secured Convertible Promissory Note – October 2020 On October 30, 2020, the Company issued to an existing investor in and lender to the Company a 10 111,111 100,000 0.07 70 0.05 The obligations of the Company under the note are secured by a senior lien and security interest in all of the assets of the Company. The Company recorded approximately $ 9,000 The interest rate on the note was 10 18 Additionally, the Company issued the noteholder 1,587,301 0.08 0.05 952,379 57,000 0.16 262.27 0.92 The Company recorded a discount related to the warrants of approximately $ 66,000 6,000 5,000 45,000 69,000 5,000 4,000 On January 27, 2022, the exercise price of the notes and warrants was adjusted from the default conversion price of $ 0.049 0.039 For the three and six months ended June 30, 2022, the Company recognized approximately $ 5,000 10,000 For the three and six-month periods ended June 30, 2021, the Company recognized approximately $ 5,000 9,700 1,000 2,600 20,000 79,000 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2022 (Unaudited) As of June 30, 2022, the Company has outstanding principal of $ 111,111 29,000 As of June 30, 2022, the Company remains in default on the repayment of principal and interest on the notes. Upon demand for repayment at the election of the holder, the holder of the note is due 125 The 25% premium will be recorded once a demand occurs. Secured Convertible Promissory Note – January 202 On January 31, 2021, the Company issued to an existing investor in and lender to the Company a 10 52,778 47,500 5,278 0.07 70 The obligations of the Company under the Note are secured by a senior lien and security interest in all assets of the Company. Additionally, the Company issued to the investor 753,968 0.08 0.05 452,372 27,000 0.16 262.27 0.97 The Company recorded approximately $ 2,000 The interest rate on the note was 10 18 The Company recorded a discount related to the warrants of approximately $ 32,000 3,000 1,000 0.45 240.83 The Company also recorded a debt discount related to the convertible debt of approximately $ 2,000 1,000 Total discounts recorded including the original issue discount were approximately $ 35,000 On January 27, 2022, the exercise price of the notes and warrants was adjusted from the default conversion price of $ 0.049 0.039 340,250 For the three and six months ended June 30, 2022, the Company recognized approximately $ 2,400 4,800 For the three and six-month periods ended June 30, 2021, the Company recognized approximately $ 1,700 2,900 400 700 11,000 29,000 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2022 (Unaudited) As of June 30, 2022, the Company has outstanding principal of $ 52,778 11,500 As of June 30, 2022, the Company remains in default on the repayment of principal and accrued interest on the notes. Upon demand for repayment at the election of the holder, the holder of the note is due 125 The 25% premium will be recorded once a demand occurs. Secured Convertible Promissory Note – April 2021 On April 12, 2021, the Company issued to an accredited investor in and lender to the Company a 10 66,667 60,000 6,667 800,000 five 0.095 The note matured on October 12, 2021, Prior to default, interest accrued on the aggregate unconverted and then outstanding principal amount of the note at the rate of 10 18 The Note is convertible, in whole or in part, at any time, and from time to time, into shares of the common stock of the Company at the option of the noteholder at a conversion price of $ 0.075 70 The Company recorded a discount related to the warrants of approximately $ 34,000 3,700 3,000 0.89 240.64 one On June 25, 2021, the exercise price of the warrants was adjusted to $ 0.075 213,333 11,000 0.92 247.52 0.96 On November 4, 2021, the Company issued 153,227 250,000 On November 30, 2021, the exercise price of the warrants was adjusted to $ 0.05 0.05 131,667 On January 27, 2022, the exercise price of the note and warrants was adjusted from the default conversion price of $ 0.0525 0.039 322,949 For the three and six months ended June 30, 2022, the Company recognized approximately $ 3,000 6,000 1,500 16,000 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2022 (Unaudited) As of June 30, 2022, the Company has recorded $ 66,667 12,100 As of June 30, 2022, the Company remains in default on the repayment of principal and accrued interest on the notes. Upon demand for repayment at the election of the holder, the holder of the note is due 125 The 25% premium will be recorded once a demand occurs Secured Convertible Promissory Note – June 2021 On June 25, 2021, the Company issued to an accredited investor in and lender to the Company a 5 66,500 63,000 3,500 800,000 six 0.095 76,000 The note matured on June 25, 2022 10 % per annum, calculated on the basis of a 365-day year. The Note is convertible, in whole or in part, at any time, and from time to time, into shares of the common stock of the Company at the option of the noteholder at a conversion price of $ 0.075 0.08 65 The obligations of the Company under the Note are secured by a senior lien and security interest in all assets of the Company. The Company incurred approximately $ 9,300 The Company also issued 47,547 5,040 Due to the variability in the conversion price of the Note the embedded conversion option has been bifurcated and reflected as a derivative liability with an initial fair value of $ 102,823 87,039 Total discounts recorded were $ 66,500 3,500 9,300 37,916 15,784 0.48 302.11 0.60 On August 11, 2021, the exercise price of the warrants was adjusted to $ 0.075 213,333 25,000 0.81 209 0.57 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2022 (Unaudited) On October 27, 2021, the Company and the institutional investor who holds the convertible promissory note agreed to extend the maturity date of the note by six months to December 25, 2022 for no consideration. On November 30, 2021, the exercise price of the warrants was adjusted to $ 0.05 0.05 506,667 On January 27, 2022, the holder of the June 25, 2021, convertible note converted $ 9,500 421 0.039 254,401 28,000 18,000 23,000 23,000 5,000 0.039 428,718 For the three and six months ended June 30, 2022, the Company recognized approximately $ 9,900 19,600 3,400 7,000 100.00 4,400 As of June 30, 2022, the Company has recorded $ 57,000 12,200 19,000 Convertible Promissory Note – August 11, 2021 On August 11, 2021, the Company entered into a Securities Purchase Agreement with an accredited institutional investor pursuant to which the Company issued to the investor its Original Issue Discount Secured Convertible Promissory Note in the principal amount of $ 220,500 800,000 210,000 10,500 100,000 The note matured on August 11, 2022 10 0.075 65 24 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2022 (Unaudited) In addition to customary anti-dilution adjustments the Note provides, subject to certain limited exceptions, that if the Company issues any common stock or common stock equivalents, as defined in the Note, at a per share price lower than the conversion price then in effect, the conversion price will be reduced to the per share price at which such shares or common share equivalents were sold. The warrants are initially exercisable for a period of six years at a price of $ 0.095 The Company incurred approximately $ 30,000 The Company also issued 140,000 Due to the variability in the conversion price of the Note the embedded conversion option has been bifurcated and reflected as a derivative liability with an initial fair value of $ 340,893 234,388 106,505 The Company recorded a total debt discount of $ 220,500 10,500 56,454 30,000 17,041 106,505 The fair value of the warrants on which the relative fair value was based was determined by using a simple binomial lattice model. The assumptions used in the model were a risk-free rate of 0.81 253 one On November 30, 2021, the exercise price of the warrants was adjusted to $ 0.05 0.05 720,000 On January 27, 2022, the conversion price of the notes was adjusted to the lower of $ 0.039 65 0.039 428,718 0.039 On May 12, 2022, the Company repaid $ 135,695 64,305 54,278 September 30, 2022 128,502 45,200 For the three and six months ended June 30, 2022, the Company recognized approximately $ 40,000 94,000 73,000 85,400 67,000 As of June 30, 2022, the Company has remaining $ 85,000 37,000 40,000 Convertible Promissory Note – August 17, 2021 On August 17, 2021, the Company entered into a Securities Purchase Agreement with an accredited institutional investor pursuant to which the Company issued to the investor its Original Issue Discount Secured Convertible Promissory Note in the principal amount of $ 220,500 800,000 210,000 10,500 100,000 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2022 (Unaudited) The note matures on August 17, 2022 10 0.075 0.08 65 In addition to customary anti-dilution adjustments the Note provides, subject to certain limited exceptions, that if the Company issues any common stock or common stock equivalents, as defined in the Note, at a per share price lower than the conversion price then in effect, the conversion price will be reduced to the per share price at which such shares or common share equivalents were sold. The Warrants are initially exercisable for a period of six years at a price of $ 0.095 The Company incurred approximately $ 30,000 112,601 Due to the variability in the conversion price of the Note, the embedded conversion option has been bifurcated and reflected as a derivative liability with an initial fair value of $ 398,404 297,833 100,571 The Company recorded a total debt discount of $ 220,500 10,500 62,220 30,000 17,209 100,571 The fair value of the warrants on which the relative fair value was based was determined by using a simple binomial lattice model. The assumptions used in the model were a risk-free rate of 0.77 254 On October 27, 2021, the Company and the institutional investor who holds the promissory note agreed to extend the maturity date the notes by six months to February 17, 2023 for no consideration. On November 15, 2021, the Company defaulted on certain covenants in the note and the interest rate on the note reset to 24% On November 30, 2021, the exercise price of the warrants was adjusted to $ 0.05 0.05 720,000 On January 27, 2022, the conversion price of the notes was adjusted to the lower of $ 0.039 65 0.039 428,718 0.039 For the three and six months ended June 30, 2022, the Company recognized approximately $ 35,000 69,700 12,600 25,000 As of June 30, 2022, the Company has recorded $ 220,500 40,400 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2022 (Unaudited) Convertible Promissory Note – October 4, 2021 On October 4, 2021, the Company entered into a Securities Purchase Agreement (“SPA”) with an institutional investor pursuant to which the Company issued the Buyer a 10% Convertible Redeemable Note in the principal amount of $ 131,250 476,190 110,000 59,523 The Note is due October 4, 2022. The Note provides for interest at the rate of 10 0.075 The Warrants are exercisable for three-years from October 4, 2021, at an exercise price of $ 0.095 45,238 The Company incurred approximately $ 15,000 43,459 Due to the lack of authorized shares, the embedded conversion option has been bifurcated and reflected as a derivative liability with an initial fair value of $ 564,943 487,052 77,891 The Company recorded a total debt discount of $ 131,250 6,250 15,000 32,109 77,891 On January 2, 2022, the Company defaulted on certain covenants contained in the October 4, 2021, convertible note and the interest rate reset to 16 On January 27, 2022, the exercise price of the note was adjusted to $ 0.039 0.039 On May 12, 2022 the Company repaid $ 83,500 59,523 1,000 11,571 8,428 81,700 For the three and six months ended June 30, 2022, the Company recognized approximately $ 32,700 65,000 244 5,200 As of June 30, 2022, the Company has recorded $ 36,200 34,200 Convertible Promissory Note – October 7, 2021 On October 7, 2021, the Company entered into a Securities Purchase Agreement (“SPA”) with an institutional investor pursuant to which the Company issued the investor a 10 131,250 476,190 110,000 59,523 52,632 The Note is due October 7, 2022. The Note provides for interest at the rate of 10 0.075 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2022 (Unaudited) The Warrants are exercisable for six-years from October 7, 2021, at an exercise price of $ 0.095 45,238 The Company incurred approximately $ 15,000 Due to the lack of authorized shares, the embedded conversion option has been bifurcated and reflected as a derivative liability with an initial fair value of $ 564,184 487,667 76,517 The Company recorded a total debt discount of $ 131,250 6,250 15,000 33,483 76,517 On January 5, 2022, the Company defaulted on certain covenants contained in the October 7, 2021, convertible note and the interest rate reset to 16 On January 27, 2022, the exercise price of the note was adjusted to $ 0.039 0.039 On May 12, 2022, the Company repaid $ 83,500 59,523 1,000 11,571 8,428 82,900 For the three and six months ended June 30, 2022, the Company recognized approximately $ 32,700 65,100 295 5,300 As of June 30, 2022, the Company has recorded $ 36,200 35,200 Convertible Promissory Note – March 15, 2022 On March 15, 2022, the Company entered into a Securities Purchase Agreement (“SPA”) with an institutional investor pursuant to which the Company issued the investor a 10 250,000 200,000 50,000 180,000 20,000 50,000 200,000 The Note provides for guaranteed interest at the rate of 10 25,000 39,285.71 The Note is convertible into shares of common stock at any time following any event of default at the investor’s option at a conversion price of ninety percent (90%) per share of the lowest per-share trading price of the Company; stock during the ten trading day periods before the conversion, subject to certain adjustments. The Company recorded a total debt discount of $ 250,000 50,000 34,384 3,596 162,020 For the three and six months ended June 30, 2022, the Company recognized approximately $ 62,300 and $ 74,000 related to the amortization of debt discounts and approximately $ 25,000 in interest expense related to the note that was deemed earned as of the date of issuance. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2022 (Unaudited) At June 30, 2022, the Company has recorded $ 250,000 25,000 176,000 Derivative Liabilities Pursuant to Convertible Notes and Warrants In connection with the issuance of the unrelated party convertible notes (collectively referred to as “Notes”) and warrants (collectively referred to as “Warrants”), discussed above, the Company determined that the terms of certain Notes and Warrants contain an embedded conversion options to be accounted for as derivative liabilities due to the holder having the potential to gain value upon conversion and provisions which includes events not within the control of the Company. Due to the fact that the number of shares of common stock potentially issuable exceed the Company’s authorized share limit as of June 30, 2022, the equity environment was tainted and all convertible debentures and warrants were included in the value of the derivative. In accordance with ASC 815-40 – Derivatives and Hedging – Contracts in an Entity’s Own Stock For the six-month period ended June 30, 2022, in connection with the issuance of the Notes and warrants, on the initial measurement dates, the fair values of the embedded conversion option of approximately $ 1,422,000 1,314,000 108,000 At the end of the period, the Company revalued the embedded conversion option derivative liabilities. In connection with the initial valuations and these revaluations, the Company recorded a gain from the initial and change in the derivative liabilities fair value of approximately $ 1,789 During the six months period ended June 30, 2022, the fair value of the derivative liabilities was estimated at issuance and at June 30, 2022, using the Binomial Lattice valuation model with the following assumptions: Schedule of Fair Value of Derivative Liabilities Estimated Issuance and Valuation Mode Dividend rate — % Term (in years) 0.0 1.07 Volatility 206 317.47 % Risk-free interest rate 1.28 3.01 % Other than the effect on the derivative valuation recognized in operations, there was no accounting effect to the ratchet adjustments of certain convertible notes to reduce the conversion price to $ 0.039 |
Licensing Agreements
Licensing Agreements | 6 Months Ended |
Jun. 30, 2022 | |
Licensing Agreements | |
Licensing Agreements | Note 5 - Licensing Agreements License of DiLA 2 On March 16, 2018, the Company entered into an exclusive sublicensing agreement for certain intellectual property rights to its DiLA2 delivery system. The agreement included an upfront payment of $ 200,000 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2022 (Unaudited) |
Related Party Transactions
Related Party Transactions | 6 Months Ended |
Jun. 30, 2022 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | Note 6 - Related Party Transactions Due to Related Party The Company and other related entities have had a commonality of ownership and/or management control, and as a result, the reported operating results and/or financial position of the Company could significantly differ from what would have been obtained if such entities were autonomous. The Company had a Master Services Agreement (“MSA”) with Autotelic Inc., a related party that is partly owned by one of the Company’s former Board members and executive officers, namely Vuong Trieu, Ph.D., effective November 15, 2016. The MSA stated that Autotelic Inc. would provide business functions and services to the Company and allowed Autotelic Inc. to charge the Company for these expenses paid on its behalf. Dr. Trieu resigned as a director of our company effective October 1, 2018. The Company and Autotelic Inc. agreed to terminate the MSA effective October 31, 2018. 4,000 In addition, as of June 30, 2022, and December 31, 2021, the Company owed various officers and directors approximately $ 42,000 |
Stockholders_ Equity
Stockholders’ Equity | 6 Months Ended |
Jun. 30, 2022 | |
Equity [Abstract] | |
Stockholders’ Equity | Note 7 - Stockholders’ Equity Preferred Stock Adhera has authorized 100,000 1,000 90,000 No 1,200 220 3,500 2,200 6,000 Series C Preferred Each share of Series C Preferred has a stated value of $ 5,000 5,100 voting rights of 666.67 votes per share 7.50 As of June 30, 2022, and December 31, 2021, 100 Series D Preferred Each share of Series D Preferred has a stated value of $ 5,000 300 voting rights of 1,250 votes per share 4.00 5 As of June 30, 2022, and December 31, 2021, 40 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2022 (Unaudited) Series E Convertible Preferred Stock and Warrants The Series E Preferred Stock has a stated value of $ 5,000 8 0.50 February 10, 2020 On March 19, 2021, the exercise price of the Series E warrants was adjusted from $ 0.50 0.05 25,900 518,000 390,000 0.16 262.27 .41 .43 As of May 17, 2021, the six-year anniversary of the closing of the Series E Preferred stock offering, all outstanding Series E Preferred stock may be converted by the Company into common stock upon written notification being provided by the Company to stockholders. As of June 30, 2022, the Company has not provided notice of conversion to the holders of the Series E Preferred stock. On June 8, 2021, an investor converted 8 10,000 101,010 53,571 75,000 On July 30, 2021, an investor converted 50 250,000 500,000 On October 4, 2021, the Company issued 255,540 20 27,770 On October 5, 2021, the Company issued 385,414 30 42,707 On October 8, 2021, the Company issued 51,414 4 5,707 On October 12, 2021, the Company issued 64,312 5 7,156 On November 23, 2021, the Company issued 193,299 15 21,649 On January 27, 2022, the exercise price of the Series E warrants was adjusted to $ 0.039 0.039 On May 17, 2022, the Company effected the conversion of 3,059 5.1 40,706,120 0.50 As of June 30, 2022, the Company had a total of 30,405,600 0.039 The Company had accrued dividends on the Series E Preferred stock of approximately $ 445,000 5.0 As of June 30, 2022, and December 31, 2021, there were 267 3,326 Series F Convertible Preferred Shares and Warrants The Series F Preferred Stock has a stated value of $ 5,000 8 0.50 February 10, 2020 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2022 (Unaudited) On October 30, 2019, the Company repurchased 20 150,000 100,000 100,000 On March 19, 2021, the exercise price of the Series F warrants was adjusted from $ 0.50 0.05 25,900 518,000 31,000 0.16 262.27 .46 .53 On October 15, 2021, the Company issued 37,043 3 3,521 As of November 9, 2021, the six-year anniversary of the closing of the Series F Preferred stock offering, all outstanding Series F Preferred stock may be converted by the Company into common stock upon written notification being provided by the Company to stockholders. As of December 31, 2021, the Company has not provided notice of conversion to the holders of the Series F Preferred stock. As of December 31, 2021, the Company had a total of 3,088,500 On May 17, 2022, the Company effected the conversion of 358 shares of Series F Preferred stock and accrued dividends of approximately $ 541,000 into 4,662,524 shares of unregistered common stock at a conversion rate of $ 0.50 per share The Company had accrued dividends on the Series F Preferred stock of approximately $ 448,000 , as of December 31, 2021. No dividends were accrued as of June 30, 2022. At June 30, 2022 and December 31, 2021, there were zero 358 Series G Convertible Preferred Shares The Series G Preferred Stock has a stated value of $ 5,000 8 0.50 As of June 30, 2022, no Common Stock On June 8, 2021, an investor converted 8 10,000 101,010 On June 8, 2021, the Company issued 53,571 75,000 On July 30, 2021, and investor converted 50 250,000 500,000 On August 11, 2021, the Company issued 100,000 56,464 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2022 (Unaudited) On August 18, 2021, the Company issued 100,000 62,220 On September 22, 2021, the Company issued 300,148 39,290 On October 4, 2021, the Company issued 255,540 20 27,770 On October 4, 2021, the Company issued 59,523 10,859 On October 5, 2021, the Company issued 385,414 30 42,707 On October 8, 2021, the Company issued 51,414 4 5,707 On October 8, 2021, the Company issued 59,523 12,233 On October 15, 2021, the Company issued 37,043 3 3,521 On November 4, 2021, the Company issued 153,227 250,000 On December 6, 2021, the Company issued 96,091 18,745 During the twelve-month period ending December 31, 2021, the company issued 3,366,012 98,141 70,160 554,000 386,000 On January 27, 2022, the Company issued 254,401 9,500 422 28,000 18,000 23,000 23,000 5,000 On March 15, 2022, the Company issued 50,000 3,596 On March 15, 2022, the Company issued 200,000 14,384 On May 17, 2022, the Company effected the conversion of 3,059 5.1 40,706,120 0.50 On May 17, 2022, the Company effected the conversion of 358 541,000 4,662,524 0.50 Treasury Stock On May 12, 2022, the Company repurchased 119,046 2,000 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2022 (Unaudited) Warrants As of June 30, 2022, there were 102,665,674 0.04 Schedule of Stockholders’ Equity Note, Warrants or Rights Shares 2023 2024 2025 2026 2027 Series E Preferred Stock 30,405,600 30,405,600 Series F Preferred Stock 3,088,500 3,088,500 Bridge Loan 22,222,218 22,222,218 Convertible Notes (CVN) 46,590,623 2,901,098 36,777,552 6,911,974 Other 348,733 10,080 335,452 3,201 Total Warrants 102,655,674 33,504,180 3,236,550 36,780,753 6,911,974 22,222,218 Schedule of Warrants Shares Warrants as of December 31, 2021 74,625,139 Issued as a result of price adjustments on CVN 2,665,672 Variable quantity of warrants related to February 2020 note 3,142,645 Warrants issued with 2022 Bridge Note 22,222,218 Warrants as of June 30, 2022 102,665,674 Warrants outstanding as of June 30, 2022, included 101,354,561 The intrinsic value of 102,665,674 2.0 As discussed in Note 2 above, the Company has issued convertible notes and warrants with variable conversion provisions. The conversion terms of the convertible notes are variable based on certain factors, such as the future price of the Company’s common stock and various default provisions related to the payment of the notes in Company stock. The number of shares of common stock to be issued under the convertible notes and warrants is based on the future price of the Company’s common stock. The number of shares of common stock potentially issuable upon conversion of the promissory notes are therefore, indeterminate. Due to the fact that the number of shares of common stock potentially issuable exceed the Company’s authorized share limit as of June 30, 2022, the equity environment was tainted and all convertible debentures and warrants were included in the value of the derivative as of that date. Pursuant to ASC 815-15 Embedded Derivatives, the fair values of the warrants were recorded as derivative liabilities. On June 30, 2022, the Company evaluated all outstanding warrants and due to reasons discussed above, all warrants outstanding were considered tainted and were therefore, accounted for as derivative liabilities. Other than the effect on the derivative valuation recognized in operations, there was no accounting effect to the ratchet adjustments of certain warrants to reduce the conversion price to $ 0.039 |
Stock Incentive Plans
Stock Incentive Plans | 6 Months Ended |
Jun. 30, 2022 | |
Share-Based Payment Arrangement [Abstract] | |
Stock Incentive Plans | NOTE 8 - Stock Incentive Plans Stock Options The following table summarizes stock option activity for the six-month period ended June 30, 2022: Schedule of Share Based Payments Arrangement, Option Activity Options Outstanding Shares Weighted Average Exercise Price Outstanding, December 31, 2021 384,050 $ 0.97 Options expired / forfeited (4,050 ) 1.70 Outstanding, June 30, 2022 380,000 0.98 Exercisable, June 30, 2022 380,000 $ 0.98 No stock options were granted during the six-month period ended June 30, 2022. The following table summarizes additional information on the Company’s stock options outstanding at June 30, 2022: Schedule of Share Based Payment Arrangement, Option, Exercise Price Range Options Outstanding Options Exercisable Exercise Price Number Outstanding Weighted- Average Remaining Contractual Life (Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $0.98 380,000 0.84 $ 0.98 380,000 $ 0.98 Totals 380,000 0.84 $ 0.98 380,000 $ 0.98 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2022 (Unaudited) As of June 30, 2022, the Company had no unrecognized compensation expense related to unvested stock options. No As of June 30, 2022, the intrinsic value of options outstanding or exercisable was zero there were no options outstanding with an exercise price less than $ 0.07 |
Commitments and Contingencies
Commitments and Contingencies | 6 Months Ended |
Jun. 30, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | NOTE 9 - Commitments and Contingencies Litigation Because of the nature of the Company’s business, it is subject to claims and/or threatened legal actions, which arise out of the normal course of business. As of the date of this filing, the Company is not aware of any pending lawsuits against it, its officers or directors. Leases The Company does not own or lease any real property or facilities that are material to its current business operations. If the Company continues its business operations, the Company may seek to lease facilities in order to support its operational and administrative needs. Share Repurchase Agreement On October 30, 2019, the Company repurchased 20 150,000 100,000 100,000 Licensing Agreement – MLR 1019 On July 28, 2021, the Company and Melior II entered into an exclusive license agreement for the development, commercialization and exclusive license of MLR-1019. MLR-1019 is being developed as a new class of therapeutic for Parkinson’s disease (PD) and is, to the best of the Company’s knowledge, the only drug candidate today to address both movement and non-movement aspects of PD. Under the Agreement, the Company was granted an exclusive license to use Melior II’s Patents and know-how to develop products in consideration for cash payments up to approximately $ 21.8 5 The license terminates upon the last expiration of the patents licensed by the Company, which is presently 2034 subject extensions and renewals of any of such patents. If the Company fails to have its common stock listed on Nasdaq or the NYSE (an “Uplisting Event”) within 12 months after the Company receives a Clinical Trial Authorization from the European Medicines Agency, then the Company’s commercial license and rights for using Melior II’s data shall terminate. Additionally, if the Company has completed the necessary steps to effect an Uplisting Event, the Company will have the option to purchase all rights held by Melior II on the MLR-1019 licensed products in consideration for 10 2.5 As of June 30, 2022, no performance milestones had been met under the agreement. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2022 (Unaudited) Licensing Agreement – MLR 1023 On August 24, 2021, the Company as licensee entered into an exclusive license agreement with Melior I for the development, commercialization and exclusive license of Melior I’s MLR-1023. MLR-1023 is being developed as a novel therapeutic for Type 1 diabetes. Under the Agreement, the Company was granted an exclusive license to use the Melior I’s Patents and know-how to develop products in consideration for cash payments up to approximately $ 21.8 8 12 Under the original terms of the agreement if the Company failed to raise $4.0 million dollars within 120 days of the Effective Date then the License would immediately terminate unless, by 120 Days Adhera was in the process of completing transactions to complete the fundraising then an additional 30 Days would be provided to allow for the completion of the raise On October 20, 2021, the Company expanded the exclusive licensing agreement with Melior I to include two additional clinical indications for Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation. On November 17, 2021, Melior I extended the Company’s timeline from 120 days to 180 days from the effective of the agreement for the Company to raise $4.0 million dollars unless, by 180 Days Adhera is in the process of completing transactions to complete the fundraising then an additional 30 Days shall be provided to allow for the completion of required fundraising On February 16, 2022, an addendum to the licensing agreement dated August 4, 2021, was executed by the Company and Melior I, extending the requirement by the Company to raise $4.0 million dollars to June 16, 2022 As of June 30, 2022, no performance milestones had been met under the agreement. |
Subsequent Events
Subsequent Events | 6 Months Ended |
Jun. 30, 2022 | |
Subsequent Events [Abstract] | |
Subsequent Events | NOTE 10 - Subsequent Events Licensing Agreement – MLR 1023 On July 20, 2022, the Company entered into an addendum to the License Agreement for MLR-1023 with Melior I pursuant to which Melior I extended the license to February 1, 2023 in exchange for a $ 136,921 500,000 |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2022 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, they do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”) for complete financial statements. This quarterly report should be read in conjunction with the consolidated financial statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The information furnished in this Report reflects all adjustments (consisting of normal recurring adjustments), which are, in the opinion of management, necessary for a fair presentation of our financial position, results of operations and cash flows for each period presented. The results of operations for the six months ended June 30, 2022, are not necessarily indicative of the results for the year ending December 31, 2022 or for any future period. |
Principles of Consolidation | Principles of Consolidation The consolidated financial statements include the accounts of Adhera Therapeutics, Inc. and the wholly-owned subsidiaries, Ithena, Cequent, MDRNA, and Atossa, and eliminate any inter-company balances and transactions. All wholly-owned subsidiaries of Adhera Therapeutics, Inc. are inactive. |
Going Concern and Management’s Liquidity Plans | Going Concern and Management’s Liquidity Plans The accompanying consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business. As of June 30, 2022, the Company had cash and cash equivalents of approximately $ 849,000 20.0 The Company has incurred recurring losses and negative cash flows from operations since inception and has funded its operating losses through the sale of common stock, preferred stock, warrants to purchase common stock, convertible notes and secured promissory notes. The Company recognized net income of approximately $ 25,000 690,000 53.6 In addition, to the extent that the Company continues its business operations, the Company anticipates that it will continue to have negative cash flows from operations, at least into the near future. However, the Company cannot be certain that it will be able to obtain such funds required for its our operations at terms acceptable to the Company or at all. General market conditions, as well as market conditions for companies in the Company’s financial and business position, as well as the ongoing issues arising from the COVID-19 pandemic, the Ukraine war and inflation and the Federal Reserve interest rate increases in response, may make it difficult for the Company to seek financing from the capital markets, and the terms of any financing may adversely affect the holdings or the rights of its stockholders. If the Company is unable to obtain additional financing in the future, there may be a negative impact on the financial viability of the Company. The Company plans to increase working capital by managing its cash flows and expenses, divesting development assets and raising additional capital through private or public equity or debt financing. There can be no assurance that such financing or partnerships will be available on terms which are favorable to the Company or at all. While management of the Company believes that it has a plan to fund ongoing operations, there is no assurance that its plan will be successfully implemented. Failure to raise additional capital through one or more financings, divesting development assets or reducing discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance date of this Report. The consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties. Summary of Significant Accounting Policies |
Cash and Cash Equivalents | Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of six months or less at the time of purchase to be cash equivalents. As of June 30, 2022, the Company had approximately $ 849,000 The Company deposits its cash with major financial institutions that may at times exceed the federally insured limit. As of June 30, 2022 the Company had $ 599,000 250,000 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2022 (Unaudited) |
Use of Estimates | Use of Estimates The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include accruals related to our operating activity including legal and other consulting expenses, the fair value of non-cash equity-based issuances, the fair value of derivative liabilities, and the valuation allowance on deferred tax assets. Actual results could differ materially from such estimates under different assumptions or circumstances. |
Fair Value of Financial Instruments | Fair Value of Financial Instruments The Company considers the fair value of cash, accounts payable, debt, and accrued expenses not to be materially different from their carrying value. These financial instruments have short-term maturities. We follow authoritative guidance with respect to fair value reporting issued by the Financial Accounting Standards Board (“FASB”) for financial assets and liabilities, which defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into six broad levels. The following is a brief description of those six levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. As of June 30, 2022, the Company measured conversion features on outstanding convertible notes and warrants as a derivative liability using significant unobservable prices that are based on little or no verifiable market data, which is Level 3 in the fair value hierarchy, resulting in a fair value estimate of approximately $ 7.1 2.80 3.01 206.01 317.47 1.07 no Schedule of Fair Value Measurements (in thousands) (Level 1) (Level 2) (Level 3) Total Fair Value Measurements at June 30, 2022 Quoted Other Significant (in thousands) (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 7,098 $ 7,098 Total $ - $ - $ 7,098 $ 7,098 ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2022 (Unaudited) A roll forward of the level 3 valuation financial instruments is as follows: Schedule of Roll Forward of Level 3 Financial Instruments (In thousands) Warrants Notes Total Six-Months Ended June 30, 2022 (In thousands) Warrants Notes Total Balance at December 31, 2021 $ 5,336 $ 2,361 $ 7,697 Initial valuation of derivative liabilities included in debt discount 1,151 163 1,314 Initial valuation of derivative liabilities included in derivative expense — 108 108 Reclassification of derivative liabilities loss to gain on debt extinguishment — (233 ) (233 ) Change in fair value included in derivative expense (617 ) (1,171 ) (1,788 ) Balance at June 30, 2022 $ 5,870 $ 1,228 $ 7,098 ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding equity instruments. |
Convertible Debt and Warrant Accounting | Convertible Debt and Warrant Accounting Debt with warrants In accordance with ASC Topic 470-20-25, when the Company issues debt with warrants, the Company treats the relative fair value of the warrants as a debt discount, recorded as a contra-liability against the debt, and amortizes the balance over the life of the underlying debt as amortization of debt discount expense in the consolidated statements of operations. The offset to the contra-liability is recorded as additional paid in capital in the Company’s consolidated balance sheets if the warrants are not treated as a derivative. The Company determines the fair value of the warrants using the Black-Scholes Option Pricing Model (“Black-Scholes”), the binomial model or the Monte Carlo Method based upon the underlying conversion features of the debt and then computes and records the relative fair value as a debt discount. If the debt is retired early, the associated debt discount is then recognized immediately as amortization of debt discount expense in the consolidated statements of operations. Convertible debt – derivative treatment When the Company issues debt with a conversion feature, it first assesses whether the conversion feature meets the requirements to be accounted for as stock settled debt. If it does not meet those requirements then it is assessed on whether the conversion feature should be bifurcated and treated as a derivative liability, as follows: a) one or more underlyings, typically the price of our common stock; b) one or more notional amounts or payment provisions or both, generally the number of shares upon conversion; c) no initial net investment, which typically excludes the amount borrowed; and d) net settlement provisions, which in the case of convertible debt generally means the stock received upon conversion can be readily sold for cash. An embedded equity-linked component that meets the definition of a derivative does not have to be separated from the host instrument if the component qualifies for the scope exception for certain contracts involving an issuer’s own equity. The scope exception applies if the contract is both a) indexed to its own stock; and b) classified in stockholders’ equity in its statement of financial position. Convertible debt – beneficial conversion feature Prior to the Company’s adoption of ASU No. 2020-06, Debt—Debt with Conversion and Other Options Derivatives and Hedging—Contracts in Entity’s Own Equity Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2022 (Unaudited) If the conversion feature does not qualify for derivative treatment, the convertible debt is treated as traditional debt. |
Recently Issued Accounting Pronouncements | Recently Issued Accounting Pronouncements Recently Adopted In January 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-04, Intangibles-Goodwill and Other (Topic 350) (“ASU 2017-04”), which will simplify the goodwill impairment calculation by eliminating Step 2 from the current goodwill impairment test. The new standard does not change how a goodwill impairment is identified. The Company will continue to perform its quantitative goodwill impairment test by comparing the fair value of its reporting unit to its carrying amount, but if the Company is required to recognize a goodwill impairment charge, under the new standard, the amount of the charge will be calculated by subtracting the reporting unit’s fair value from its carrying amount. Under the current standard, if the Company is required to recognize a goodwill impairment charge, Step 2 requires it to calculate the implied value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination and the amount of the charge is calculated by subtracting the reporting unit’s implied fair value of goodwill from the goodwill carrying amount. The standard was effective January 1, 2020. The adoption of ASU 2017-04 did not have a material impact on the Company’s historical consolidated financial statements. In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which will simplify the accounting for certain financial instruments with characteristics of liabilities and equity, including certain convertible instruments and contracts on an entity’s own equity. Specifically, the new standard will remove the separation models required for convertible debt with cash conversion features and convertible instruments with beneficial conversion features. It will also remove certain settlement conditions that are currently required for equity contracts to qualify for the derivative scope exception and will simplify the diluted earnings per share calculation for convertible instruments. ASU 2020-06 will be effective January 1, 2022, for the Company and may be applied using a full or modified retrospective approach. Early adoption is permitted, but no earlier than January 1, 2021, for the Company. The Company adopted ASU No. 2020-06 on January 1, 2021. Management determined such adoption did not have a material impact on the overall stockholders’ equity (deficit) in the Company’s consolidated financial statements. In May 2021, FASB issued ASU 2021-04: Earnings Per Share (Topic 260), Debt— Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40), to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in ASU 2021-04 provide the following guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic: 1. An entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as an exchange of the original instrument for a new instrument. 2. An entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as follows: a. For a modification or an exchange that is a part of or directly related to a modification or an exchange of an existing debt instrument or line-of-credit or revolving-debt arrangements (hereinafter, referred to as a “debt” or “debt instrument”), as the difference between the fair value of the modified or exchanged written call option and the fair value of that written call option immediately before it is modified or exchanged. Specifically, an entity should consider: i. An increase or a decrease in the fair value of the modified or exchanged written call option in applying the 10 percent cash flow test and/or calculating the fees between debtor and creditor in accordance with Subtopic 470-50, Debt—Modifications and Extinguishments. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2022 (Unaudited) ii. An increase (but not a decrease) in the fair value of the modified or exchanged written call option in calculating the third-party costs in accordance with Subtopic 470-50. b. For all other modifications or exchanges, as the excess, if any, of the fair value of the modified or exchanged written call option over the fair value of that written call option immediately before it is modified or exchanged. 3. An entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange on the basis of the substance of the transaction, in the same manner as if cash had been paid as consideration, as follows: a. A financing transaction to raise equity. The effect should be recognized as an equity issuance cost in accordance with the guidance in Topic 340, Other Assets and Deferred Costs. b. A financing transaction to raise or modify debt. The effect should be recognized as a cost in accordance with the guidance in Topic 470, Debt, and Topic 835, Interest. c. Other modifications or exchanges that are not related to financings or compensation for goods or services or other exchange transactions within the scope of another Topic. The effect should be recognized as a dividend. For entities that present EPS in accordance with Topic 260, that dividend should be an adjustment to net income (or net loss) in the basic EPS calculation. An entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option to compensate for goods or services in accordance with the guidance in Topic 718, Compensation—Stock Compensation. In a multiple-element transaction (for example, one that includes both debt financing and equity financing), the total effect of the modification should be allocated to the respective elements in the transaction. The amendments in ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt the amendments in ASU 2021-04 in an interim period, the guidance should be applied as of the beginning of the fiscal year. The adoption by the Company as of January 1, 2022 did not have a significant impact on its financial statements. Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures. |
Net Loss per Common Share | Net Loss per Common Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. Potentially dilutive securities which include outstanding warrants, stock options, convertible notes and preferred stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. For all periods presented, basic and diluted net loss were the same. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2022 (Unaudited) The following table presents the computation of net loss per share (in thousands), except share and per share data): Schedule of Earnings Per Share, Basic and Diluted Three Months Ended Six Months Ended 2022 2021 2022 2021 Numerator Net income (loss) $ 99 $ (514 ) $ 25 $ (942 ) Accrued and deemed dividends (406 ) (392 ) (566 ) (1,274 ) Net Loss allocable to common stockholders $ (307 ) $ (906 ) $ (541 ) $ (2,216 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic and diluted 22,801,669 11,669,779 40,078,424 11,270,044 Net loss per share of common stock, basic and diluted Net loss per share $ (0.01 ) $ (0.08 ) $ (0.01 ) $ (0.20 ) The following number of shares have been excluded from diluted net (loss) since such inclusion would be anti-dilutive: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Six-Months Ended June 30, 2022 2021 Stock options outstanding 380,000 387,550 Convertible notes 48,802,730 20,952,683 Warrants 102,655,674 59,836,767 Series C Preferred Stock 66,667 66,667 Series D Preferred Stock 50,000 50,000 Series E Preferred Stock 3,559,229 43,325700 Series F Preferred Stock — 4,446,980 Total 155,514,300 129,066,417 As of June 30, 2022, the Company’s fully diluted common stock and equivalents exceeded the 180,000,000 |
Stock-Based Compensation | Stock-Based Compensation The Company applies the provisions of ASC 718, Compensation—Stock Compensation (“ASC 718”) For stock options issued, the Company estimates the grant date fair value of each option using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based vesting conditions, including those with a graded vesting schedule, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting term. Forfeitures are recorded as they are incurred as opposed to being estimated at the time of grant and revised if and when a forfeiture becomes probable. ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Three and Six Months Ended June 30, 2022 (Unaudited) |
Income Taxes | Income Taxes Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss and credit carry forwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Accounting Policies [Abstract] | |
Schedule of Fair Value Measurements | Schedule of Fair Value Measurements (in thousands) (Level 1) (Level 2) (Level 3) Total Fair Value Measurements at June 30, 2022 Quoted Other Significant (in thousands) (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 7,098 $ 7,098 Total $ - $ - $ 7,098 $ 7,098 |
Schedule of Roll Forward of Level 3 Financial Instruments | A roll forward of the level 3 valuation financial instruments is as follows: Schedule of Roll Forward of Level 3 Financial Instruments (In thousands) Warrants Notes Total Six-Months Ended June 30, 2022 (In thousands) Warrants Notes Total Balance at December 31, 2021 $ 5,336 $ 2,361 $ 7,697 Initial valuation of derivative liabilities included in debt discount 1,151 163 1,314 Initial valuation of derivative liabilities included in derivative expense — 108 108 Reclassification of derivative liabilities loss to gain on debt extinguishment — (233 ) (233 ) Change in fair value included in derivative expense (617 ) (1,171 ) (1,788 ) Balance at June 30, 2022 $ 5,870 $ 1,228 $ 7,098 |
Schedule of Earnings Per Share, Basic and Diluted | The following table presents the computation of net loss per share (in thousands), except share and per share data): Schedule of Earnings Per Share, Basic and Diluted Three Months Ended Six Months Ended 2022 2021 2022 2021 Numerator Net income (loss) $ 99 $ (514 ) $ 25 $ (942 ) Accrued and deemed dividends (406 ) (392 ) (566 ) (1,274 ) Net Loss allocable to common stockholders $ (307 ) $ (906 ) $ (541 ) $ (2,216 ) Denominator Weighted average common shares outstanding used to compute net loss per share, basic and diluted 22,801,669 11,669,779 40,078,424 11,270,044 Net loss per share of common stock, basic and diluted Net loss per share $ (0.01 ) $ (0.08 ) $ (0.01 ) $ (0.20 ) |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share | The following number of shares have been excluded from diluted net (loss) since such inclusion would be anti-dilutive: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Six-Months Ended June 30, 2022 2021 Stock options outstanding 380,000 387,550 Convertible notes 48,802,730 20,952,683 Warrants 102,655,674 59,836,767 Series C Preferred Stock 66,667 66,667 Series D Preferred Stock 50,000 50,000 Series E Preferred Stock 3,559,229 43,325700 Series F Preferred Stock — 4,446,980 Total 155,514,300 129,066,417 |
Notes Payable and Convertible_2
Notes Payable and Convertible Promissory Notes (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Debt Disclosure [Abstract] | |
Schedule of Outstanding Term Loans | The following table summarizes the Company’s outstanding term loans: Schedule of Outstanding Term Loans (in thousands) June 30, 2022 December 30, 2021 2019 Term Loan $ 5,677 $ 5,677 2022 Term Loan 2,222 - Notes payable 7,899 5,677 Unamortized discounts (1,592 ) - Loans payable $ 6,307 $ 5,677 |
Schedule of Convertible Promissory Notes | The following table summarizes the Company’s outstanding convertible notes as of June 30, 2022, and December 31, 2021: Schedule of Convertible Promissory Notes (in thousands) June 30, 2022 December 31, 2021 Convertible Notes $ 1,431 $ 1,516 Unamortized discounts and fees (392 ) (530 ) Convertible notes payable, net $ 1,039 $ 986 |
Schedule of Fair Value of Derivative Liabilities Estimated Issuance and Valuation Mode | During the six months period ended June 30, 2022, the fair value of the derivative liabilities was estimated at issuance and at June 30, 2022, using the Binomial Lattice valuation model with the following assumptions: Schedule of Fair Value of Derivative Liabilities Estimated Issuance and Valuation Mode Dividend rate — % Term (in years) 0.0 1.07 Volatility 206 317.47 % Risk-free interest rate 1.28 3.01 % |
Stockholders_ Equity (Tables)
Stockholders’ Equity (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Equity [Abstract] | |
Schedule of Stockholders’ Equity Note, Warrants or Rights | Schedule of Stockholders’ Equity Note, Warrants or Rights Shares 2023 2024 2025 2026 2027 Series E Preferred Stock 30,405,600 30,405,600 Series F Preferred Stock 3,088,500 3,088,500 Bridge Loan 22,222,218 22,222,218 Convertible Notes (CVN) 46,590,623 2,901,098 36,777,552 6,911,974 Other 348,733 10,080 335,452 3,201 Total Warrants 102,655,674 33,504,180 3,236,550 36,780,753 6,911,974 22,222,218 |
Schedule of Warrants | Schedule of Warrants Shares Warrants as of December 31, 2021 74,625,139 Issued as a result of price adjustments on CVN 2,665,672 Variable quantity of warrants related to February 2020 note 3,142,645 Warrants issued with 2022 Bridge Note 22,222,218 Warrants as of June 30, 2022 102,665,674 |
Stock Incentive Plans (Tables)
Stock Incentive Plans (Tables) | 6 Months Ended |
Jun. 30, 2022 | |
Share-Based Payment Arrangement [Abstract] | |
Schedule of Share Based Payments Arrangement, Option Activity | The following table summarizes stock option activity for the six-month period ended June 30, 2022: Schedule of Share Based Payments Arrangement, Option Activity Options Outstanding Shares Weighted Average Exercise Price Outstanding, December 31, 2021 384,050 $ 0.97 Options expired / forfeited (4,050 ) 1.70 Outstanding, June 30, 2022 380,000 0.98 Exercisable, June 30, 2022 380,000 $ 0.98 |
Schedule of Share Based Payment Arrangement, Option, Exercise Price Range | The following table summarizes additional information on the Company’s stock options outstanding at June 30, 2022: Schedule of Share Based Payment Arrangement, Option, Exercise Price Range Options Outstanding Options Exercisable Exercise Price Number Outstanding Weighted- Average Remaining Contractual Life (Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $0.98 380,000 0.84 $ 0.98 380,000 $ 0.98 Totals 380,000 0.84 $ 0.98 380,000 $ 0.98 |
Schedule of Fair Value Measurem
Schedule of Fair Value Measurements (Details) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 |
Defined Benefit Plan Disclosure [Line Items] | ||
Derivative liability | $ 7,098 | $ 7,697 |
Total | 7,098 | |
Fair Value, Inputs, Level 1 [Member] | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Derivative liability | ||
Total | ||
Fair Value, Inputs, Level 2 [Member] | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Derivative liability | ||
Total | ||
Fair Value, Inputs, Level 3 [Member] | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Derivative liability | 7,098 | |
Total | $ 7,098 |
Schedule of Roll Forward of Lev
Schedule of Roll Forward of Level 3 Financial Instruments (Details) $ in Thousands | 6 Months Ended |
Jun. 30, 2022 USD ($) | |
Short-Term Debt [Line Items] | |
Balance at December 31, 2021 | $ 7,697 |
Initial valuation of derivative liabilities included in debt discount | 1,314 |
Initial valuation of derivative liabilities included in derivative expense | 108 |
Reclassification of derivative liabilities loss to gain on debt extinguishment | (233) |
Change in fair value included in derivative expense | (1,788) |
Balance at June 30, 2022 | 7,098 |
Warrants [Member] | |
Short-Term Debt [Line Items] | |
Balance at December 31, 2021 | 5,336 |
Initial valuation of derivative liabilities included in debt discount | 1,151 |
Initial valuation of derivative liabilities included in derivative expense | |
Reclassification of derivative liabilities loss to gain on debt extinguishment | |
Change in fair value included in derivative expense | (617) |
Balance at June 30, 2022 | 5,870 |
Convertible Notes [Member] | |
Short-Term Debt [Line Items] | |
Balance at December 31, 2021 | 2,361 |
Initial valuation of derivative liabilities included in debt discount | 163 |
Initial valuation of derivative liabilities included in derivative expense | 108 |
Reclassification of derivative liabilities loss to gain on debt extinguishment | (233) |
Change in fair value included in derivative expense | (1,171) |
Balance at June 30, 2022 | $ 1,228 |
Schedule of Earnings Per Share,
Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 6 Months Ended | ||||
Jun. 30, 2022 | Mar. 31, 2022 | Jun. 30, 2021 | Mar. 31, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Accounting Policies [Abstract] | ||||||
Net income (loss) | $ 99 | $ (74) | $ (514) | $ (428) | $ 25 | $ (942) |
Accrued and deemed dividends | (406) | (392) | (566) | (1,274) | ||
Net Loss allocable to common stockholders | $ (307) | $ (906) | $ (541) | $ (2,216) | ||
Weighted average common shares outstanding used to compute net loss per share, basic and diluted | 22,801,669 | 11,669,779 | 40,078,424 | 11,270,044 | ||
Net loss per share | $ (0.01) | $ (0.08) | $ (0.01) | $ (0.20) |
Schedule of Antidilutive Securi
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares | 6 Months Ended | |
Jun. 30, 2022 | Jun. 30, 2021 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total | 155,514,300 | 129,066,417 |
Stock Options Outstanding [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total | 380,000 | 387,550 |
Convertible Notes Payable [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total | 48,802,730 | 20,952,683 |
Warrant [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total | 102,655,674 | 59,836,767 |
Series C Preferred Stock [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total | 66,667 | 66,667 |
Series D Preferred Stock [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total | 50,000 | 50,000 |
Series E Preferred Stock [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total | 3,559,229 | 43,325,700 |
Series F Preferred Stock [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Total | 4,446,980 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies (Details Narrative) - USD ($) | 3 Months Ended | 6 Months Ended | |||||
Jun. 30, 2022 | Mar. 31, 2022 | Jun. 30, 2021 | Mar. 31, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | Dec. 31, 2021 | |
Property, Plant and Equipment [Line Items] | |||||||
Cash and cash equivalents | $ 849,000 | $ 849,000 | |||||
Working capital | 20,000,000 | 20,000,000 | |||||
Net loss | 99,000 | $ (74,000) | $ (514,000) | $ (428,000) | 25,000 | $ (942,000) | |
Net cash used in operating activities | 690,000 | $ 118,000 | |||||
Accumulated deficit | 53,558,000 | 53,558,000 | $ 53,017,000 | ||||
Cash equivalents | 849,000 | 849,000 | $ 76,000 | ||||
Cash | 599,000 | 599,000 | |||||
Cash federally insured limit amount | 250,000 | 250,000 | |||||
Fair value, net asset liability | $ 0 | $ 0 | |||||
Common stock, shares authorized | 180,000,000 | 180,000,000 | 180,000,000 | ||||
Minimum [Member] | |||||||
Property, Plant and Equipment [Line Items] | |||||||
Fair value assumptions, risk free interest rate | 2.80% | ||||||
Fair value assumptions, volatility rate | 206.01% | ||||||
Maximum [Member] | |||||||
Property, Plant and Equipment [Line Items] | |||||||
Fair value assumptions, risk free interest rate | 3.01% | ||||||
Fair value assumptions, volatility rate | 317.47% | ||||||
Fair value assumptions, expected term | 1 year 25 days | ||||||
Fair Value, Inputs, Level 3 [Member] | |||||||
Property, Plant and Equipment [Line Items] | |||||||
Long-term debt, fair value | $ 7,100,000 | $ 7,100,000 |
Prepaid Expenses (Details Narra
Prepaid Expenses (Details Narrative) - USD ($) | Jun. 30, 2022 | Dec. 31, 2021 |
Prepaid Expenses | ||
Prepaid expenses | $ 127,000 | $ 120,000 |
Schedule of Outstanding Term Lo
Schedule of Outstanding Term Loans (Details) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 |
Short-Term Debt [Line Items] | ||
Notes payable | $ 7,899 | $ 5,677 |
Unamortized discounts | (1,592) | |
Loans payable | 6,307 | 5,677 |
Two Thousand Nineteen Term Loan [Member] | ||
Short-Term Debt [Line Items] | ||
Notes payable | 5,677 | 5,677 |
Two Thousand Twenty Two Term Loan [Member] | ||
Short-Term Debt [Line Items] | ||
Notes payable | $ 2,222 |
Schedule of Convertible Promiss
Schedule of Convertible Promissory Notes (Details) - USD ($) $ in Thousands | Jun. 30, 2022 | Dec. 31, 2021 |
Debt Disclosure [Abstract] | ||
Convertible Notes | $ 1,431 | $ 1,516 |
Unamortized discounts and fees | (392) | (530) |
Convertible notes payable, net | $ 1,039 | $ 986 |
Schedule of Fair Value of Deriv
Schedule of Fair Value of Derivative Liabilities Estimated Issuance and Valuation Mode (Details) | Jun. 30, 2022 |
Measurement Input, Expected Dividend Rate [Member] | |
Debt Instrument [Line Items] | |
Risk-free interest rate | 0 |
Measurement Input, Expected Term [Member] | Minimum [Member] | |
Debt Instrument [Line Items] | |
Term (in years) | 0 years |
Measurement Input, Expected Term [Member] | Maximum [Member] | |
Debt Instrument [Line Items] | |
Term (in years) | 1 year 25 days |
Measurement Input, Price Volatility [Member] | Minimum [Member] | |
Debt Instrument [Line Items] | |
Risk-free interest rate | 206 |
Measurement Input, Price Volatility [Member] | Maximum [Member] | |
Debt Instrument [Line Items] | |
Risk-free interest rate | 317.47 |
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member] | |
Debt Instrument [Line Items] | |
Risk-free interest rate | 1.28 |
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member] | |
Debt Instrument [Line Items] | |
Risk-free interest rate | 3.01 |
Notes Payable and Convertible_3
Notes Payable and Convertible Promissory Notes (Details Narrative) | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||||||||||||||||||||||||||||||||||||||
May 12, 2022 USD ($) shares | May 11, 2022 USD ($) $ / shares shares | Mar. 15, 2022 USD ($) shares | Jan. 27, 2022 USD ($) $ / shares shares | Jan. 05, 2022 | Nov. 30, 2021 $ / shares shares | Nov. 29, 2021 USD ($) shares | Nov. 15, 2021 $ / shares shares | Nov. 04, 2021 shares | Oct. 12, 2021 | Oct. 07, 2021 USD ($) $ / shares shares | Oct. 04, 2021 USD ($) $ / shares shares | Sep. 13, 2021 USD ($) shares | Aug. 17, 2021 USD ($) $ / shares shares | Aug. 16, 2021 USD ($) shares | Aug. 11, 2021 USD ($) $ / shares shares | Jul. 30, 2021 shares | Jul. 29, 2021 USD ($) shares | Jun. 25, 2021 USD ($) $ / shares shares | Jun. 25, 2021 USD ($) $ / shares shares | Apr. 12, 2021 USD ($) $ / shares shares | Mar. 19, 2021 USD ($) $ / shares shares | Jan. 31, 2021 USD ($) $ / shares shares | Oct. 30, 2020 USD ($) $ / shares shares | Jun. 26, 2020 USD ($) $ / shares | May 05, 2020 $ / shares | Feb. 05, 2020 USD ($) | Dec. 28, 2019 | Jul. 31, 2021 | Jun. 30, 2022 USD ($) $ / shares shares | Jun. 30, 2021 USD ($) | Mar. 31, 2021 USD ($) | Jun. 30, 2022 USD ($) $ / shares shares | Jun. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) shares | Jan. 31, 2022 $ / shares | Jan. 02, 2022 | Nov. 09, 2021 | Apr. 30, 2021 | Aug. 05, 2020 | Jun. 15, 2020 | Dec. 31, 2019 USD ($) | Oct. 30, 2019 $ / shares | Aug. 05, 2019 USD ($) | |
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 140% | 140% | ||||||||||||||||||||||||||||||||||||||||||
Repayments of debt | $ 407,000 | |||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 102,665,674 | 102,665,674 | 74,625,139 | |||||||||||||||||||||||||||||||||||||||||
Payments of Debt Issuance Costs | $ 328,000 | 12,000 | ||||||||||||||||||||||||||||||||||||||||||
Debt instrument description | (i) the 12 month anniversary of the original issuance date of the Notes, or May 11, 2023, (ii) a financing transaction which results in the Company’s common stock being listed on a national securities exchange, and (iii) an event of default. If an event of default occurs before the Company’s common stock is listed on a national securities exchange, the event of default would require a repayment of 125% of the outstanding principal, accrued interest and other amounts owing thereon unless the Company is trading on a national securities exchange in which case the repayment would be 100%. The Notes bear interest at 8% per annum, subject to an increase to 15% in case of an event of default as provided for therein. In addition, at any time before the 12-month anniversary of the date of issuance of the Notes, the Company may, upon five days’ prior written notice to the Purchaser, prepay all of the then outstanding principal amount of the Notes for cash in an amount equal to the sum of 105% of all amounts due and owing hereunder, including all accrued and unpaid interest | |||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 1,592,000 | 1,592,000 | ||||||||||||||||||||||||||||||||||||||||||
Debt discount | 488,000 | 129,000 | ||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable, current | 1,039,000 | 1,039,000 | 986,000 | |||||||||||||||||||||||||||||||||||||||||
Loss on fair value of derivative liabilities | 1,679,000 | (87,000) | ||||||||||||||||||||||||||||||||||||||||||
Interest expense related party | $ 21,000 | $ 25,000 | $ 46,000 | 50,000 | ||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 0.08 | $ 0.08 | $ 0.04 | $ 0.04 | ||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 7,899,000 | $ 7,899,000 | 5,677,000 | |||||||||||||||||||||||||||||||||||||||||
Gain on debt extinguishment | 210,000 | 215,000 | ||||||||||||||||||||||||||||||||||||||||||
Interest rate | 16% | |||||||||||||||||||||||||||||||||||||||||||
February 2020 Convertible Note [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Principal amount | 457,359 | 457,359 | 98,141 | |||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 70,160 | |||||||||||||||||||||||||||||||||||||||||||
Conversion instrument amount | $ 554,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt conversion shares issued | shares | 3,366,012 | |||||||||||||||||||||||||||||||||||||||||||
Interest payable | 147,000 | 147,000 | ||||||||||||||||||||||||||||||||||||||||||
Gain on debt extinguishment | $ 386,000 | |||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note One [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 111,111 | $ 111,111 | $ 111,111 | |||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 9,000 | |||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 10% | 125% | 125% | |||||||||||||||||||||||||||||||||||||||||
Interest expense debt | $ 5,000 | 5,000 | $ 10,000 | 9,700 | ||||||||||||||||||||||||||||||||||||||||
Accured interest | 29,000 | 29,000 | ||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of secured debt | $ 100,000 | |||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 428,718 | 952,379 | 1,587,301 | |||||||||||||||||||||||||||||||||||||||||
Warrants term | 11 months 1 day | |||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 6,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt discount | 1,000 | 20,000 | $ 2,600 | 79,000 | ||||||||||||||||||||||||||||||||||||||||
Debt instrument interest rate, effective percentage | 18% | |||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 0.07 | $ 0.05 | ||||||||||||||||||||||||||||||||||||||||||
Shares issued, price per share | $ / shares | $ 0.08 | |||||||||||||||||||||||||||||||||||||||||||
Convertible note premium description | The 25% premium will be recorded once a demand occurs. | |||||||||||||||||||||||||||||||||||||||||||
Convertible, beneficial conversion feature | $ 45,000 | |||||||||||||||||||||||||||||||||||||||||||
Beneficial conversion feature | $ 69,000 | |||||||||||||||||||||||||||||||||||||||||||
Threshold percentage | 70% | |||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 0.05 | |||||||||||||||||||||||||||||||||||||||||||
Deemed dividend | $ 57,000 | |||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note One [Member] | Minimum [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Debt and warrant exercise price per share | $ / shares | $ 0.049 | |||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note One [Member] | Maximum [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Debt and warrant exercise price per share | $ / shares | $ 0.039 | |||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note One [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 0.0016 | |||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note One [Member] | Measurement Input, Price Volatility [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 2.6227 | |||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note - January 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 52,778 | |||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | 2,000 | |||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 2,400 | 1,700 | $ 4,800 | 2,900 | ||||||||||||||||||||||||||||||||||||||||
Accured interest | $ 11,500 | $ 11,500 | ||||||||||||||||||||||||||||||||||||||||||
Original issue discount | 35,000 | |||||||||||||||||||||||||||||||||||||||||||
Warrants term | 11 months 19 days | |||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | 2,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | 400 | 700 | ||||||||||||||||||||||||||||||||||||||||||
Debt discount | 11,000 | 29,000 | ||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable, current | $ 47,500 | |||||||||||||||||||||||||||||||||||||||||||
Debt instrument interest rate, effective percentage | 10% | 125% | 125% | |||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 0.05 | $ 0.07 | ||||||||||||||||||||||||||||||||||||||||||
Convertible note premium description | The 25% premium will be recorded once a demand occurs. | |||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 0.08 | |||||||||||||||||||||||||||||||||||||||||||
Deemed dividend | $ 27,000 | |||||||||||||||||||||||||||||||||||||||||||
Conversion ratio | 0.70 | |||||||||||||||||||||||||||||||||||||||||||
Warrants issued | shares | 452,372 | 753,968 | ||||||||||||||||||||||||||||||||||||||||||
Debt default interest rate | 18% | |||||||||||||||||||||||||||||||||||||||||||
Fair value method | $ 1,000 | |||||||||||||||||||||||||||||||||||||||||||
Additional warrants issued | shares | 340,250 | |||||||||||||||||||||||||||||||||||||||||||
Notes payable | $ 52,778 | $ 52,778 | ||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note - January 2021 [Member] | Investor and lender [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | 5,278 | |||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note - January 2021 [Member] | Minimum [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Debt and warrant exercise price per share | $ / shares | $ 0.049 | |||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note - January 2021 [Member] | Maximum [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Debt and warrant exercise price per share | $ / shares | $ 0.039 | |||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note - January 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 0.0016 | |||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note - January 2021 [Member] | Measurement Input, Price Volatility [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 262.27 | |||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note April 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 66,667 | $ 66,667 | $ 66,667 | |||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 10% | 125% | 125% | |||||||||||||||||||||||||||||||||||||||||
Interest expense debt | $ 3,000 | 1,500 | $ 6,000 | 1,500 | ||||||||||||||||||||||||||||||||||||||||
Accured interest | 12,100 | 12,100 | ||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 6,667 | |||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 322,949 | 131,667 | ||||||||||||||||||||||||||||||||||||||||||
Warrants term | 1 year | |||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 34,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | 16,000 | $ 16,000 | ||||||||||||||||||||||||||||||||||||||||||
Debt discount | 3,000 | |||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable, current | $ 60,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt instrument interest rate, effective percentage | 10% | |||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 0.05 | |||||||||||||||||||||||||||||||||||||||||||
Debt conversion converted instrument rate | 70% | |||||||||||||||||||||||||||||||||||||||||||
Convertible note premium description | The 25% premium will be recorded once a demand occurs | |||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | 0.05 | |||||||||||||||||||||||||||||||||||||||||||
Debt default interest rate | 18% | |||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note April 2021 [Member] | Investor [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 800,000 | |||||||||||||||||||||||||||||||||||||||||||
Warrants term | 5 years | |||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 0.095 | |||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note April 2021 [Member] | Minimum [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 0.0525 | |||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note April 2021 [Member] | Maximum [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 0.039 | |||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note April 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 0.0089 | |||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note April 2021 [Member] | Measurement Input, Price Volatility [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 2.4064 | |||||||||||||||||||||||||||||||||||||||||||
April 2021 Convertible Note [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Shares issued for warrants exercise | shares | 153,227 | |||||||||||||||||||||||||||||||||||||||||||
Cashless exercise of warrants | shares | 250,000 | |||||||||||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note - June 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 66,500 | $ 66,500 | 57,000 | $ 57,000 | ||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 10% | 10% | ||||||||||||||||||||||||||||||||||||||||||
Maturity date | Jun. 25, 2022 | |||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | $ 421 | |||||||||||||||||||||||||||||||||||||||||||
Accured interest | 12,200 | 12,200 | ||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 3,500 | $ 3,500 | ||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 800,000 | 800,000 | ||||||||||||||||||||||||||||||||||||||||||
Warrants term | 6 years | 6 years | ||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 5,040 | $ 5,040 | 19,000 | 19,000 | ||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | 9,300 | |||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable, current | $ 63,000 | $ 63,000 | ||||||||||||||||||||||||||||||||||||||||||
Debt instrument interest rate, effective percentage | 5% | 5% | ||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 0.039 | $ 0.075 | $ 0.075 | |||||||||||||||||||||||||||||||||||||||||
Debt conversion converted instrument rate | 65% | |||||||||||||||||||||||||||||||||||||||||||
Conversion instrument amount | $ 9,500 | |||||||||||||||||||||||||||||||||||||||||||
Debt conversion shares issued | shares | 254,401 | |||||||||||||||||||||||||||||||||||||||||||
Loss on extinguishment of debt | $ 18,000 | |||||||||||||||||||||||||||||||||||||||||||
Gain on extinguishment of debt | $ 23,000 | |||||||||||||||||||||||||||||||||||||||||||
Extinguishment of debt gain loss net of tax | 5,000 | |||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 0.095 | $ 0.095 | ||||||||||||||||||||||||||||||||||||||||||
Warrants outstanding | $ 76,000 | $ 76,000 | ||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | shares | 47,547 | |||||||||||||||||||||||||||||||||||||||||||
Derivative liabilities | $ 102,823 | 102,823 | ||||||||||||||||||||||||||||||||||||||||||
Derivative expense | 87,039 | |||||||||||||||||||||||||||||||||||||||||||
Debt discount | 66,500 | 66,500 | ||||||||||||||||||||||||||||||||||||||||||
Unamortized debt issuance expense | $ 9,300 | $ 9,300 | ||||||||||||||||||||||||||||||||||||||||||
Trading securities debt | 28,000 | |||||||||||||||||||||||||||||||||||||||||||
Derivative fair value of derivative net | $ 23,000 | |||||||||||||||||||||||||||||||||||||||||||
Secured Convertible Promissory Note - August 11, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 220,500 | 85,000 | 85,000 | |||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 30,000 | |||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 10% | 24% | ||||||||||||||||||||||||||||||||||||||||||
Maturity date | Aug. 11, 2022 | |||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 73,000 | 85,400 | ||||||||||||||||||||||||||||||||||||||||||
Accured interest | 37,000 | 37,000 | ||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 10,500 | |||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 800,000 | 800,000 | ||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 220,500 | 40,000 | 40,000 | |||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 106,505 | 40,000 | 94,000 | |||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 0.039 | 0.05 | $ 0.075 | |||||||||||||||||||||||||||||||||||||||||
Debt conversion converted instrument rate | 65% | 65% | ||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 0.039 | $ 0.05 | ||||||||||||||||||||||||||||||||||||||||||
Additional warrants issued | shares | 720,000 | |||||||||||||||||||||||||||||||||||||||||||
Warrants outstanding | $ 210,000 | |||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | shares | 140,000 | |||||||||||||||||||||||||||||||||||||||||||
Derivative liabilities | $ 340,893 | |||||||||||||||||||||||||||||||||||||||||||
Derivative expense | 234,388 | |||||||||||||||||||||||||||||||||||||||||||
Debt conversion shares issued or options issued | shares | 428,718 | |||||||||||||||||||||||||||||||||||||||||||
Senior secured convertible promissory note five [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Maturity date | Sep. 30, 2022 | |||||||||||||||||||||||||||||||||||||||||||
Periodic payment Interest | $ 64,305 | |||||||||||||||||||||||||||||||||||||||||||
Debt periodic payment | 128,502 | |||||||||||||||||||||||||||||||||||||||||||
Interest payable | 54,278 | |||||||||||||||||||||||||||||||||||||||||||
Debt instrument periodic payment principal | 135,695 | |||||||||||||||||||||||||||||||||||||||||||
Gain on debt extinguishment | 45,200 | |||||||||||||||||||||||||||||||||||||||||||
Additional interest | 67,000 | |||||||||||||||||||||||||||||||||||||||||||
Secured Convertible Promissory Note - August 17, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 220,500 | 220,500 | 220,500 | |||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 30,000 | |||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 10% | |||||||||||||||||||||||||||||||||||||||||||
Maturity date | Aug. 17, 2022 | |||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 12,600 | 25,000 | ||||||||||||||||||||||||||||||||||||||||||
Accured interest | 40,400 | 40,400 | ||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 10,500 | |||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 100,571 | 35,000 | 69,700 | |||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 0.039 | $ 0.075 | ||||||||||||||||||||||||||||||||||||||||||
Debt conversion converted instrument rate | 65% | 65% | ||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 0.039 | |||||||||||||||||||||||||||||||||||||||||||
Debt and warrant exercise price per share | $ / shares | $ 0.039 | |||||||||||||||||||||||||||||||||||||||||||
Warrants outstanding | $ 210,000 | |||||||||||||||||||||||||||||||||||||||||||
Derivative liabilities | 398,404 | |||||||||||||||||||||||||||||||||||||||||||
Derivative expense | $ 297,833 | |||||||||||||||||||||||||||||||||||||||||||
Debt conversion shares issued or options issued | shares | 428,718 | |||||||||||||||||||||||||||||||||||||||||||
Secured Convertible Promissory Note - August 17, 2021 [Member] | Minimum [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 0.08 | |||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note - October 4, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 131,250 | 36,200 | 36,200 | |||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 15,000 | |||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 10% | 16% | ||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 244 | 5,200 | ||||||||||||||||||||||||||||||||||||||||||
Periodic payment Interest | 8,428 | |||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 6,250 | |||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 476,190 | |||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 131,250 | 34,200 | 34,200 | |||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 77,891 | 32,700 | 65,000 | |||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 0.039 | $ 0.075 | ||||||||||||||||||||||||||||||||||||||||||
Debt conversion shares issued | shares | 43,459 | |||||||||||||||||||||||||||||||||||||||||||
Debt periodic payment | 83,500 | |||||||||||||||||||||||||||||||||||||||||||
Warrants outstanding | $ 110,000 | |||||||||||||||||||||||||||||||||||||||||||
Derivative liabilities | 564,943 | |||||||||||||||||||||||||||||||||||||||||||
Derivative expense | 487,052 | |||||||||||||||||||||||||||||||||||||||||||
Unamortized debt issuance expense | 32,109 | |||||||||||||||||||||||||||||||||||||||||||
Debt instrument periodic payment principal | 11,571 | |||||||||||||||||||||||||||||||||||||||||||
Exercise price | 45,238 | |||||||||||||||||||||||||||||||||||||||||||
Discount related issuance cost | 15,000 | |||||||||||||||||||||||||||||||||||||||||||
Commitment fee | 1,000 | |||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note October 7, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 131,250 | 36,200 | 36,200 | |||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 15,000 | |||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 10% | |||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 5,300 | |||||||||||||||||||||||||||||||||||||||||||
Periodic payment Interest | 8,428 | |||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 6,250 | |||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 476,190 | |||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | 35,200 | 35,200 | ||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 76,517 | 131,250 | 32,700 | 65,100 | ||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | 0.039 | $ 0.075 | ||||||||||||||||||||||||||||||||||||||||||
Debt periodic payment | 83,500 | |||||||||||||||||||||||||||||||||||||||||||
Warrants outstanding | $ 110,000 | |||||||||||||||||||||||||||||||||||||||||||
Derivative liabilities | 564,184 | |||||||||||||||||||||||||||||||||||||||||||
Derivative expense | 487,667 | |||||||||||||||||||||||||||||||||||||||||||
Debt instrument periodic payment principal | 11,571 | |||||||||||||||||||||||||||||||||||||||||||
Gain on debt extinguishment | 82,900 | |||||||||||||||||||||||||||||||||||||||||||
Discount related issuance cost | 15,000 | |||||||||||||||||||||||||||||||||||||||||||
Commitment fee | $ 1,000 | |||||||||||||||||||||||||||||||||||||||||||
Aggreggate exercise price | $ 45,238 | |||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note - March 15, 2022 [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 250,000 | 250,000 | 250,000 | |||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 10% | |||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 295 | 25,000 | ||||||||||||||||||||||||||||||||||||||||||
Accured interest | 25,000 | 25,000 | ||||||||||||||||||||||||||||||||||||||||||
Original issue discount | $ 50,000 | |||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of secured debt | 200,000 | |||||||||||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | 180,000 | |||||||||||||||||||||||||||||||||||||||||||
Payments of Debt Issuance Costs | 20,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | 176,000 | 176,000 | ||||||||||||||||||||||||||||||||||||||||||
Debt discount | 250,000 | 62,300 | 74,000 | |||||||||||||||||||||||||||||||||||||||||
Debt periodic payment | $ 39,285.71 | |||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | shares | 200,000 | |||||||||||||||||||||||||||||||||||||||||||
Discount related issuance cost | $ 34,384 | |||||||||||||||||||||||||||||||||||||||||||
Guaranteed interest contracts | $ 250 | |||||||||||||||||||||||||||||||||||||||||||
Convertible Promissory Note - March 15, 2022 [Member] | Investor [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | shares | 50,000 | |||||||||||||||||||||||||||||||||||||||||||
Ten Convertible Notes [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Principal amount | 1,200,000 | 1,200,000 | ||||||||||||||||||||||||||||||||||||||||||
Convertible Debt [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 0.039 | |||||||||||||||||||||||||||||||||||||||||||
Conversion instrument amount | $ 554,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt conversion shares issued | shares | 3,366,012 | |||||||||||||||||||||||||||||||||||||||||||
Debt periodic payment | $ 168,300 | |||||||||||||||||||||||||||||||||||||||||||
Loss on extinguishment of debt | 386,000 | |||||||||||||||||||||||||||||||||||||||||||
Loss on fair value of derivative liabilities | 245,000 | |||||||||||||||||||||||||||||||||||||||||||
Gain on extinguishment of debt | 245,000 | |||||||||||||||||||||||||||||||||||||||||||
Extinguishment of debt gain loss net of tax | $ 141,000 | |||||||||||||||||||||||||||||||||||||||||||
Convertible Debt [Member] | Senior Secured Convertible Promissory Note [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 18% | |||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 0.039 | $ 0.039 | ||||||||||||||||||||||||||||||||||||||||||
Debt conversion converted instrument rate | 65% | |||||||||||||||||||||||||||||||||||||||||||
Convertible Debt [Member] | Secured Convertible Promissory Note [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 58,055 | $ 58,055 | ||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 140% | 140% | ||||||||||||||||||||||||||||||||||||||||||
Convertible note premium description | The 40% premium will be recorded once a demand occurs | |||||||||||||||||||||||||||||||||||||||||||
Accrued interest | $ 21,000 | $ 21,000 | ||||||||||||||||||||||||||||||||||||||||||
Convertible Debt [Member] | Senior Secured Convertible Promissory Note One [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 4,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt discount | 5,000 | |||||||||||||||||||||||||||||||||||||||||||
Convertible Debt [Member] | Secured Convertible Promissory Note - August 11, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | 106,505 | |||||||||||||||||||||||||||||||||||||||||||
Convertible Debt [Member] | Secured Convertible Promissory Note - August 17, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 720,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | 100,571 | |||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 0.05 | |||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 0.05 | |||||||||||||||||||||||||||||||||||||||||||
Convertible Debt [Member] | Convertible Promissory Note October 7, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 76,517 | |||||||||||||||||||||||||||||||||||||||||||
Convertible Debt [Member] | Convertible Promissory Note - March 15, 2022 [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 162,020 | |||||||||||||||||||||||||||||||||||||||||||
Convertible Note [Member] | Senior Secured Convertible Promissory Note [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 58,055 | |||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 14,000 | |||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 10% | |||||||||||||||||||||||||||||||||||||||||||
Maturity date | Dec. 26, 2020 | |||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of secured debt | $ 52,500 | |||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 5,555 | |||||||||||||||||||||||||||||||||||||||||||
Debt instrument interest rate, effective percentage | 10% | |||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 0.02 | |||||||||||||||||||||||||||||||||||||||||||
Debt conversion converted instrument rate | 65% | |||||||||||||||||||||||||||||||||||||||||||
Convertible, beneficial conversion feature | $ 50,000 | |||||||||||||||||||||||||||||||||||||||||||
Beneficial conversion feature | $ 203,000 | |||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | shares | 500,000 | |||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | Secured Convertible Promissory Note - August 11, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | 17,041 | |||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | Secured Convertible Promissory Note - August 17, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 17,209 | |||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | shares | 112,601 | |||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | Convertible Promissory Note - October 4, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 77,891 | |||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | shares | 59,523 | |||||||||||||||||||||||||||||||||||||||||||
Gain on debt extinguishment | $ 81,700 | |||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | Convertible Promissory Note October 7, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 33,483 | |||||||||||||||||||||||||||||||||||||||||||
Number of shares issued | shares | 59,523 | |||||||||||||||||||||||||||||||||||||||||||
Common Stock [Member] | Convertible Promissory Note - March 15, 2022 [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 3,596 | |||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Senior Secured Convertible Promissory Note One [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 66,000 | |||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Senior Secured Convertible Promissory Note - January 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | 1,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | 32,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 3,000 | |||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Senior Secured Convertible Promissory Note - January 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 0.0045 | |||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Senior Secured Convertible Promissory Note - January 2021 [Member] | Measurement Input, Price Volatility [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 240.83 | |||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Senior Secured Convertible Promissory Note April 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Warrants term | 11 months 15 days | |||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 3,700 | |||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 0.075 | $ 0.075 | ||||||||||||||||||||||||||||||||||||||||||
Deemed dividend | $ 11,000 | $ 11,000 | ||||||||||||||||||||||||||||||||||||||||||
Warrants issued | shares | 213,333 | |||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Senior Secured Convertible Promissory Note April 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 0.0092 | 0.0092 | ||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Senior Secured Convertible Promissory Note April 2021 [Member] | Measurement Input, Price Volatility [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 2.4752 | 2.4752 | ||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Senior Secured Convertible Promissory Note - June 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 3,400 | 7,000 | 100 | |||||||||||||||||||||||||||||||||||||||||
Warrants term | 6 months 25 days | 7 months 6 days | 7 months 6 days | |||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 37,916 | $ 37,916 | ||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | 4,400 | |||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 15,784 | 9,900 | 19,600 | |||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 0.05 | |||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 0.05 | $ 0.075 | ||||||||||||||||||||||||||||||||||||||||||
Deemed dividend | $ 25,000 | |||||||||||||||||||||||||||||||||||||||||||
Warrants issued | shares | 213,333 | |||||||||||||||||||||||||||||||||||||||||||
Additional warrants issued | shares | 506,667 | |||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Senior Secured Convertible Promissory Note - June 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 0.0081 | 0.0048 | 0.0048 | |||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Senior Secured Convertible Promissory Note - June 2021 [Member] | Measurement Input, Price Volatility [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 2.09 | 3.0211 | 3.0211 | |||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Secured Convertible Promissory Note - August 11, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Warrants term | 2 years | |||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 56,454 | |||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 0.095 | |||||||||||||||||||||||||||||||||||||||||||
Unamortized debt issuance expense | $ 30,000 | |||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Secured Convertible Promissory Note - August 11, 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 0.0081 | |||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Secured Convertible Promissory Note - August 11, 2021 [Member] | Measurement Input, Price Volatility [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 2.53 | |||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Secured Convertible Promissory Note - August 17, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 62,220 | |||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 30,000 | |||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 0.095 | |||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Secured Convertible Promissory Note - August 17, 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Debt conversion converted instrument rate | 24% | |||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 0.0077 | |||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Secured Convertible Promissory Note - August 17, 2021 [Member] | Measurement Input, Price Volatility [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Warrants and rights outstanding measurement input | 2.54 | |||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Convertible Promissory Note - October 4, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 0.095 | |||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Convertible Promissory Note October 7, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Warrants exercise price per share | $ / shares | $ 0.095 | |||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Secured Convertible Promissory Note Two [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Debt discount | 1,314,000 | |||||||||||||||||||||||||||||||||||||||||||
Loss on fair value of derivative liabilities | 1,789 | |||||||||||||||||||||||||||||||||||||||||||
Derivative liabilities | 1,422,000 | 1,422,000 | ||||||||||||||||||||||||||||||||||||||||||
Derivative expense | 108,000 | |||||||||||||||||||||||||||||||||||||||||||
Term Loan Subscription Agreements [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 5,700,000 | |||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 2,600 | $ 5,300 | 2,600 | 5,300 | ||||||||||||||||||||||||||||||||||||||||
Registration Rights Agreement [Member] | Secured Convertible Promissory Note - August 11, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Debt conversion shares issued | shares | 100,000 | |||||||||||||||||||||||||||||||||||||||||||
Registration Rights Agreement [Member] | Secured Convertible Promissory Note - August 17, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Debt conversion shares issued | shares | 100,000 | |||||||||||||||||||||||||||||||||||||||||||
Registration Rights Agreement [Member] | Convertible Promissory Note - October 4, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Debt conversion shares issued | shares | 59,523 | |||||||||||||||||||||||||||||||||||||||||||
Registration Rights Agreement [Member] | Convertible Promissory Note October 7, 2021 [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Debt conversion shares issued | shares | 59,523 | |||||||||||||||||||||||||||||||||||||||||||
Debt conversion shares issued or options issued | shares | 52,632 | |||||||||||||||||||||||||||||||||||||||||||
Accredited Investors [Member] | Term Loan Subscription Agreements [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 5,700,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 707,000 | |||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 12% | |||||||||||||||||||||||||||||||||||||||||||
Debt instrument, interest during period | 15% | |||||||||||||||||||||||||||||||||||||||||||
Maturity date | Jun. 28, 2020 | |||||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 212,000 | $ 422,000 | 212,000 | $ 422,000 | ||||||||||||||||||||||||||||||||||||||||
Accured interest | 2,400,000 | 2,400,000 | ||||||||||||||||||||||||||||||||||||||||||
Repayments of debt | 5,700,000 | |||||||||||||||||||||||||||||||||||||||||||
Periodic payment Interest | $ 2,400,000 | |||||||||||||||||||||||||||||||||||||||||||
Accredited Investors [Member] | Securities purchase agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Principal amount | $ 550,500 | |||||||||||||||||||||||||||||||||||||||||||
Interest rate, percentage | 10% | 18% | ||||||||||||||||||||||||||||||||||||||||||
Maturity date | Aug. 05, 2020 | |||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 381,000 | |||||||||||||||||||||||||||||||||||||||||||
Convertible notes payable, current | $ 499,950 | |||||||||||||||||||||||||||||||||||||||||||
Debt instrument interest rate, effective percentage | 10% | |||||||||||||||||||||||||||||||||||||||||||
Conversion price | $ / shares | $ 0.50 | |||||||||||||||||||||||||||||||||||||||||||
Weighted average percentage | 70% | |||||||||||||||||||||||||||||||||||||||||||
Debt conversion converted instrument rate | 60% | 60% | ||||||||||||||||||||||||||||||||||||||||||
Stock combinations | $ / shares | $ 0.05 | |||||||||||||||||||||||||||||||||||||||||||
Shares issued, price per share | $ / shares | $ 0.039 | |||||||||||||||||||||||||||||||||||||||||||
Accredited Investors [Member] | Securities purchase agreement [Member] | Convertible Debt [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | $ 38,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 21,000 | |||||||||||||||||||||||||||||||||||||||||||
Accredited Investors [Member] | Securities purchase agreement [Member] | Convertible Note [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Conversion instrument amount | $ 31,150 | $ 26,250 | $ 32,500 | $ 25,000 | $ 27,500 | $ 25,900 | ||||||||||||||||||||||||||||||||||||||
Debt conversion shares issued | shares | 623,012 | 525,000 | 650,000 | 500,000 | 550,000 | 518,000 | ||||||||||||||||||||||||||||||||||||||
Convertible note premium description | The 40% premium will be recorded once a demand occurs | |||||||||||||||||||||||||||||||||||||||||||
Accredited Investors [Member] | Securities purchase agreement [Member] | Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Warrants term | 5 years | |||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 322,000 | |||||||||||||||||||||||||||||||||||||||||||
Accredited Investors [Member] | Securities purchase agreement [Member] | Warrant [Member] | Convertible Debt [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | 53,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 30,000 | |||||||||||||||||||||||||||||||||||||||||||
Investors [Member] | Common Stock [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 1,151,000 | |||||||||||||||||||||||||||||||||||||||||||
Investors [Member] | Securities purchase agreement [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Principal amount | 2,222,222 | 2,222,222 | $ 2,222,222 | |||||||||||||||||||||||||||||||||||||||||
Interest expense debt | 25,100 | |||||||||||||||||||||||||||||||||||||||||||
Accured interest | 25,100 | 25,100 | ||||||||||||||||||||||||||||||||||||||||||
Original issue discount | 222,222 | |||||||||||||||||||||||||||||||||||||||||||
Proceeds from issuance of secured debt | $ 2,000,000 | |||||||||||||||||||||||||||||||||||||||||||
Class of warrants | shares | 22,222,218 | |||||||||||||||||||||||||||||||||||||||||||
Proceeds from Convertible Debt | $ 1,692,200 | |||||||||||||||||||||||||||||||||||||||||||
Payments of Debt Issuance Costs | $ 307,800 | |||||||||||||||||||||||||||||||||||||||||||
Warrants term | 66 months | |||||||||||||||||||||||||||||||||||||||||||
Warrants maturity date | Nov. 11, 2027 | |||||||||||||||||||||||||||||||||||||||||||
Warrant exercise price increase decrease | $ / shares | $ 0.04 | |||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 1,693 | 1,592,000 | 1,592,000 | |||||||||||||||||||||||||||||||||||||||||
Debt issuance costs | 307,800 | |||||||||||||||||||||||||||||||||||||||||||
Debt discount | $ 100,640 | $ 100,640 | ||||||||||||||||||||||||||||||||||||||||||
Investors [Member] | Securities purchase agreement [Member] | Common Stock [Member] | ||||||||||||||||||||||||||||||||||||||||||||
Short-Term Debt [Line Items] | ||||||||||||||||||||||||||||||||||||||||||||
Debt discount to be amortized | $ 11,820 |
Licensing Agreements (Details N
Licensing Agreements (Details Narrative) | Mar. 16, 2018 USD ($) |
Accrued Liabilities [Member] | Sub-Licensing Agreement [Member] | |
Upfront payment agreement for license agreement | $ 200,000 |
Related Party Transactions (Det
Related Party Transactions (Details Narrative) - USD ($) | Jun. 30, 2022 | Dec. 31, 2021 |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||
Due to related party | $ 46,000 | $ 46,000 |
Officers And Directors [Member] | ||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||
Due from related parties | 42,000 | 42,000 |
Master Services Agreement [Member] | ||
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||
Due to related party | $ 4,000 | $ 4,000 |
Schedule of Stockholders_ Equit
Schedule of Stockholders’ Equity Note, Warrants or Rights (Details) | Jun. 30, 2022 shares |
Class of Stock [Line Items] | |
Warrant shares | 102,655,674 |
Expiring in 2023 | 33,504,180 |
Expiring in 2026 | 6,911,974 |
Expiring in 2024 | 3,236,550 |
Expiring in 2025 | 36,780,753 |
Expiring in 2027 | 22,222,218 |
Bridge Loan [Member] | |
Class of Stock [Line Items] | |
Expiring in 2026 | 22,222,218 |
Convertible Notes [Member] | |
Class of Stock [Line Items] | |
Warrant shares | 46,590,623 |
Expiring in 2026 | 6,911,974 |
Expiring in 2024 | 2,901,098 |
Expiring in 2025 | 36,777,552 |
Other [Member] | |
Class of Stock [Line Items] | |
Warrant shares | 348,733 |
Expiring in 2023 | 10,080 |
Expiring in 2024 | 335,452 |
Expiring in 2025 | 3,201 |
Series E Preferred Stock [Member] | |
Class of Stock [Line Items] | |
Warrant shares | 30,405,600 |
Expiring in 2023 | 30,405,600 |
Series F Preferred Stock [Member] | |
Class of Stock [Line Items] | |
Warrant shares | 3,088,500 |
Expiring in 2023 | 3,088,500 |
Bridge Loan [Member] | |
Class of Stock [Line Items] | |
Warrant shares | 22,222,218 |
Schedule of Warrants (Details)
Schedule of Warrants (Details) | 6 Months Ended |
Jun. 30, 2022 shares | |
Equity [Abstract] | |
Warrants, Beginning Balance | 74,625,139 |
Issued as a result of price adjustments on CVN | 2,665,672 |
Variable quantity of warrants related to February 2020 note | 3,142,645 |
Warrants issued with 2022 Bridge Note | 22,222,218 |
Warrants, Ending Balance | 102,665,674 |
Stockholders_ Equity (Details N
Stockholders’ Equity (Details Narrative) | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||||||||||||||||||||||||||||||
May 17, 2022 USD ($) $ / shares shares | May 12, 2022 USD ($) shares | Mar. 15, 2022 USD ($) shares | Jan. 27, 2022 USD ($) $ / shares shares | Jan. 27, 2022 USD ($) $ / shares | Dec. 06, 2021 USD ($) shares | Nov. 23, 2021 USD ($) shares | Nov. 04, 2021 shares | Oct. 15, 2021 USD ($) shares | Oct. 12, 2021 USD ($) shares | Oct. 08, 2021 USD ($) | Oct. 08, 2021 USD ($) shares | Oct. 05, 2021 USD ($) shares | Oct. 04, 2021 USD ($) shares | Sep. 22, 2021 USD ($) shares | Aug. 18, 2021 USD ($) shares | Aug. 11, 2021 USD ($) shares | Jul. 30, 2021 USD ($) shares | Jun. 25, 2021 USD ($) $ / shares | Jun. 08, 2021 USD ($) shares | Mar. 19, 2021 USD ($) $ / shares shares | Oct. 30, 2019 USD ($) shares | Jun. 30, 2022 USD ($) $ / shares shares | Mar. 31, 2022 USD ($) shares | Jun. 30, 2021 USD ($) | Mar. 31, 2021 USD ($) | Jun. 30, 2022 USD ($) $ / shares shares | Jun. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) $ / shares shares | Jan. 31, 2022 $ / shares | Dec. 31, 2019 shares | Jul. 31, 2018 shares | Apr. 30, 2018 shares | Aug. 31, 2015 shares | Mar. 31, 2014 shares | |
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Preferred stock, shares authorized | 100,000 | 100,000 | 100,000 | ||||||||||||||||||||||||||||||||
Stated value per share | $ / shares | $ 0.01 | $ 0.01 | $ 0.01 | ||||||||||||||||||||||||||||||||
Weighted average exercise price | $ / shares | $ 0.08 | 0.04 | 0.04 | ||||||||||||||||||||||||||||||||
Conversion rate per share | $ / shares | $ 0.006 | $ 0.006 | $ 0.006 | ||||||||||||||||||||||||||||||||
Warrant, shares | 102,665,674 | 102,665,674 | 74,625,139 | ||||||||||||||||||||||||||||||||
Warrants outstanding | 102,655,674 | 102,655,674 | |||||||||||||||||||||||||||||||||
Extinguishment of debt | $ | $ 210,000 | $ 215,000 | |||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, Conversion of Convertible Securities | $ | 11,000 | $ 28,000 | $ 26,000 | ||||||||||||||||||||||||||||||||
Intrinsic value | $ | 2,000,000 | 2,000,000 | |||||||||||||||||||||||||||||||||
Convertible Debt [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Debt conversion | $ | $ 554,000 | ||||||||||||||||||||||||||||||||||
Common shares issued | 3,366,012 | ||||||||||||||||||||||||||||||||||
Loss on extinguishment of debt | $ | $ 386,000 | ||||||||||||||||||||||||||||||||||
[custom:GainOnExtinguishmentOfDebt] | $ | 245,000 | ||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Gain (Loss), Net of Tax | $ | 141,000 | ||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | $ 0.039 | ||||||||||||||||||||||||||||||||||
April 2021 Convertible Note [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Cashless exercise of warrants | 250,000 | ||||||||||||||||||||||||||||||||||
Shares issued for warrants exercise | 153,227 | ||||||||||||||||||||||||||||||||||
February 2020 Convertible Note [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Debt conversion | $ | $ 554,000 | ||||||||||||||||||||||||||||||||||
Common shares issued | 3,366,012 | ||||||||||||||||||||||||||||||||||
Principal amount | $ | 457,359 | $ 457,359 | $ 98,141 | ||||||||||||||||||||||||||||||||
Accrued interest | $ | 70,160 | ||||||||||||||||||||||||||||||||||
Extinguishment of debt | $ | $ 386,000 | ||||||||||||||||||||||||||||||||||
Senior Secured Convertible Promissory Note [Member] | Convertible Debt [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Debt instrument, convertible, conversion price | $ / shares | $ 0.039 | $ 0.039 | $ 0.039 | ||||||||||||||||||||||||||||||||
Banking Agreement [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Stock issued during period, shares, new issues | 200,000 | 96,091 | 300,148 | ||||||||||||||||||||||||||||||||
Fair value | $ | $ 14,384 | $ 18,745 | $ 39,290 | ||||||||||||||||||||||||||||||||
Convertible Note Investor [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Stock issued during period, shares, new issues | 50,000 | 254,401 | 59,523 | 59,523 | 100,000 | 100,000 | |||||||||||||||||||||||||||||
Fair value | $ | $ 3,596 | $ 12,233 | $ 10,859 | $ 62,220 | $ 56,464 | ||||||||||||||||||||||||||||||
Accrued interest | $ | $ 422 | ||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, Conversion of Convertible Securities | $ | 9,500 | ||||||||||||||||||||||||||||||||||
Debt Securities, Trading | $ | 28,000 | $ 28,000 | |||||||||||||||||||||||||||||||||
Loss on extinguishment of debt | $ | 18,000 | ||||||||||||||||||||||||||||||||||
Derivative, Fair Value, Net | $ | $ 23,000 | 23,000 | |||||||||||||||||||||||||||||||||
[custom:GainOnExtinguishmentOfDebt] | $ | $ 23,000 | ||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Gain (Loss), Net of Tax | $ | $ 5,000 | ||||||||||||||||||||||||||||||||||
Series E Preferred [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Stock issued during period, shares, new issues | 255,540 | ||||||||||||||||||||||||||||||||||
Series F Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Warrants outstanding | 3,088,500 | ||||||||||||||||||||||||||||||||||
Series E Warrants [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Weighted average exercise price | $ / shares | $ 0.039 | $ 0.039 | |||||||||||||||||||||||||||||||||
Debt conversion | $ | $ 25,900 | ||||||||||||||||||||||||||||||||||
Common shares issued | 518,000 | ||||||||||||||||||||||||||||||||||
Series E Warrants [Member] | Maximum [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Weighted average exercise price | $ / shares | $ 0.50 | ||||||||||||||||||||||||||||||||||
Series E Warrants [Member] | Minimum [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Weighted average exercise price | $ / shares | $ 0.05 | ||||||||||||||||||||||||||||||||||
Series E Preferred [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Conversion of shares | 3,059 | 15 | 5 | 4 | 30 | 20 | 50 | 8 | |||||||||||||||||||||||||||
Accrued dividends | $ | $ 5,100,000 | $ 10,000 | |||||||||||||||||||||||||||||||||
Accrued dividends shares | 40,706,120 | 101,010 | |||||||||||||||||||||||||||||||||
Stock issued during period, shares, new issues | 193,299 | 64,312 | 51,414 | 385,414 | 255,540 | 500,000 | 53,571 | ||||||||||||||||||||||||||||
Cashless exercise of warrants | 75,000 | ||||||||||||||||||||||||||||||||||
Conversion of stock, amount converted | $ | $ 250,000 | ||||||||||||||||||||||||||||||||||
Fair value | $ | $ 21,649 | $ 7,156 | $ 5,707 | $ 42,707 | $ 27,770 | ||||||||||||||||||||||||||||||
Conversion rate per share | $ / shares | $ 0.50 | ||||||||||||||||||||||||||||||||||
Common Stock [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Stock issued during period, shares, new issues | 500,000 | ||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, Conversion of Convertible Securities | $ | 2,000 | 2,000 | 3,000 | ||||||||||||||||||||||||||||||||
Preferred and accrued dividends [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Accrued dividends | $ | $ 5,100,000 | ||||||||||||||||||||||||||||||||||
Series e preferred and accrued dividends [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Accrued dividends shares | 40,706,120 | ||||||||||||||||||||||||||||||||||
Series F Warrants [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Debt conversion | $ | $ 25,900 | ||||||||||||||||||||||||||||||||||
Common shares issued | 518,000 | ||||||||||||||||||||||||||||||||||
Series F Warrants [Member] | Maximum [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Weighted average exercise price | $ / shares | $ 0.50 | ||||||||||||||||||||||||||||||||||
Series F Warrants [Member] | Minimum [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Weighted average exercise price | $ / shares | $ 0.05 | ||||||||||||||||||||||||||||||||||
Series F Preferred [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Conversion of shares | 358 | 3 | |||||||||||||||||||||||||||||||||
Accrued dividends | $ | $ 541,000 | ||||||||||||||||||||||||||||||||||
Accrued dividends shares | 4,662,524 | ||||||||||||||||||||||||||||||||||
Stock issued during period, shares, new issues | 37,043 | ||||||||||||||||||||||||||||||||||
Fair value | $ | $ 3,521 | ||||||||||||||||||||||||||||||||||
Conversion rate per share | $ / shares | $ 0.50 | ||||||||||||||||||||||||||||||||||
Preferred and accrued dividend [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Accrued dividends | $ | $ 541,000 | ||||||||||||||||||||||||||||||||||
Series f preferred and accrued dividend [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Accrued dividends shares | 4,662,524 | ||||||||||||||||||||||||||||||||||
Treasury Stock [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Stock repurchased during period, shares | 119,046 | ||||||||||||||||||||||||||||||||||
Stock Issued During Period, Value, Conversion of Convertible Securities | $ | |||||||||||||||||||||||||||||||||||
Commitment fee | $ | $ 2,000 | ||||||||||||||||||||||||||||||||||
Warrant [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Warrants outstanding | 102,665,674 | 102,665,674 | |||||||||||||||||||||||||||||||||
Adjustable warrants | 101,354,561 | 101,354,561 | |||||||||||||||||||||||||||||||||
Series B Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Preferred stock designated shares | 1,000 | ||||||||||||||||||||||||||||||||||
Series A Junior Participating Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Preferred stock designated shares | 90,000 | 90,000 | |||||||||||||||||||||||||||||||||
Series A Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Preferred stock, shares outstanding | 0 | 0 | |||||||||||||||||||||||||||||||||
Series C Convertible Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Preferred stock, shares authorized | 1,200 | 1,200 | 1,200 | ||||||||||||||||||||||||||||||||
Preferred stock designated shares | 1,200 | ||||||||||||||||||||||||||||||||||
Preferred stock, shares outstanding | 100 | 100 | 100 | ||||||||||||||||||||||||||||||||
Stated value per share | $ / shares | $ 0.01 | $ 0.01 | $ 0.01 | ||||||||||||||||||||||||||||||||
Preferred stock shares issued | 100 | 100 | 100 | ||||||||||||||||||||||||||||||||
Series D Convertible Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Preferred stock, shares authorized | 220 | 220 | 220 | ||||||||||||||||||||||||||||||||
Preferred stock designated shares | 220 | ||||||||||||||||||||||||||||||||||
Preferred stock, shares outstanding | 40 | 40 | 40 | ||||||||||||||||||||||||||||||||
Stated value per share | $ / shares | $ 0.01 | $ 0.01 | $ 0.01 | ||||||||||||||||||||||||||||||||
Preferred stock shares issued | 40 | 40 | 40 | ||||||||||||||||||||||||||||||||
Series E Convertible Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Preferred stock, shares authorized | 3,500 | 3,500 | 3,500 | ||||||||||||||||||||||||||||||||
Preferred stock designated shares | 3,500 | ||||||||||||||||||||||||||||||||||
Preferred stock, shares outstanding | 267 | 267 | 267 | ||||||||||||||||||||||||||||||||
Stated value per share | $ / shares | $ 0.01 | $ 0.01 | $ 0.01 | ||||||||||||||||||||||||||||||||
Preferred stock shares issued | 267 | 267 | 267 | ||||||||||||||||||||||||||||||||
Series F Convertible Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Preferred stock, shares authorized | 2,200 | 2,200 | 2,200 | ||||||||||||||||||||||||||||||||
Preferred stock designated shares | 2,200 | ||||||||||||||||||||||||||||||||||
Preferred stock, shares outstanding | 0 | 0 | 358 | ||||||||||||||||||||||||||||||||
Stated value per share | $ / shares | $ 0.01 | $ 0.01 | $ 0.01 | ||||||||||||||||||||||||||||||||
Conversion of shares | 358 | ||||||||||||||||||||||||||||||||||
Accrued dividends | $ | $ 0 | $ 0 | $ 448,000 | ||||||||||||||||||||||||||||||||
Warrant, shares | 150,000 | ||||||||||||||||||||||||||||||||||
Stock repurchased during period, shares | 20 | ||||||||||||||||||||||||||||||||||
Shares repurchase | $ | $ 100,000 | ||||||||||||||||||||||||||||||||||
Warrants held | $ | $ 100,000 | ||||||||||||||||||||||||||||||||||
Preferred stock shares issued | 0 | 0 | 358 | ||||||||||||||||||||||||||||||||
Series G Convertible Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Preferred stock, shares authorized | 6,000 | 6,000 | 6,000 | ||||||||||||||||||||||||||||||||
Preferred stock designated shares | 6,000 | ||||||||||||||||||||||||||||||||||
Preferred stock, shares outstanding | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||
Stated value per share | $ / shares | $ 0.01 | $ 0.01 | $ 0.01 | ||||||||||||||||||||||||||||||||
Preferred stock shares issued | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||
Series C Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Preferred stock, shares outstanding | 100 | 100 | 100 | ||||||||||||||||||||||||||||||||
Stated value per share | $ / shares | $ 5,000 | $ 5,000 | |||||||||||||||||||||||||||||||||
Preferred stock liquidation preference per share | $ / shares | 5,100 | $ 5,100 | |||||||||||||||||||||||||||||||||
Preferred Stock, Voting Rights | voting rights of 666.67 votes per share | ||||||||||||||||||||||||||||||||||
Common stock at a conversion price, per share | $ / shares | $ 7.50 | $ 7.50 | |||||||||||||||||||||||||||||||||
Series D Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Preferred stock, shares outstanding | 40 | 40 | 40 | ||||||||||||||||||||||||||||||||
Stated value per share | $ / shares | $ 5,000 | $ 5,000 | |||||||||||||||||||||||||||||||||
Preferred stock liquidation preference per share | $ / shares | 300 | $ 300 | |||||||||||||||||||||||||||||||||
Preferred Stock, Voting Rights | voting rights of 1,250 votes per share | ||||||||||||||||||||||||||||||||||
Common stock at a conversion price, per share | $ / shares | 4 | $ 4 | |||||||||||||||||||||||||||||||||
Preferred stock stated dividend rate | 5% | ||||||||||||||||||||||||||||||||||
Series E Convertible Preferred Stock and Warrants [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Stated value per share | $ / shares | 5,000 | $ 5,000 | |||||||||||||||||||||||||||||||||
Common stock at a conversion price, per share | $ / shares | $ 0.50 | $ 0.50 | |||||||||||||||||||||||||||||||||
Preferred stock stated dividend rate | 8% | ||||||||||||||||||||||||||||||||||
Antidilution price protection | Feb. 10, 2020 | ||||||||||||||||||||||||||||||||||
Series E Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Preferred stock, shares outstanding | 267 | 267 | 3,326 | ||||||||||||||||||||||||||||||||
Weighted average exercise price | $ / shares | $ 0.039 | $ 0.039 | |||||||||||||||||||||||||||||||||
Deemed dividend | $ | $ 390,000 | ||||||||||||||||||||||||||||||||||
Accrued dividends | $ | $ 445,000 | $ 445,000 | $ 5,000,000 | ||||||||||||||||||||||||||||||||
Warrant, shares | 30,405,600 | 30,405,600 | |||||||||||||||||||||||||||||||||
Warrants outstanding | 30,405,600 | 30,405,600 | |||||||||||||||||||||||||||||||||
Series E Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Fair value of warrants measurement inputs | 0.0016 | ||||||||||||||||||||||||||||||||||
Series E Preferred Stock [Member] | Measurement Input, Price Volatility [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Fair value of warrants measurement inputs | 2.6227 | ||||||||||||||||||||||||||||||||||
Series E Preferred Stock [Member] | Maximum [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Warrant term | 5 months 4 days | ||||||||||||||||||||||||||||||||||
Series E Preferred Stock [Member] | Minimum [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Warrant term | 4 months 28 days | ||||||||||||||||||||||||||||||||||
Series F Convertible Preferred Stock and Warrants [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Stated value per share | $ / shares | $ 5,000 | $ 5,000 | |||||||||||||||||||||||||||||||||
Common stock at a conversion price, per share | $ / shares | $ 0.50 | $ 0.50 | |||||||||||||||||||||||||||||||||
Preferred stock stated dividend rate | 8% | ||||||||||||||||||||||||||||||||||
Antidilution price protection | Feb. 10, 2020 | ||||||||||||||||||||||||||||||||||
Series F Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Deemed dividend | $ | $ 31,000 | ||||||||||||||||||||||||||||||||||
Warrants outstanding | 3,088,500 | 3,088,500 | |||||||||||||||||||||||||||||||||
Series F Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Fair value of warrants measurement inputs | 0.0016 | ||||||||||||||||||||||||||||||||||
Series F Preferred Stock [Member] | Measurement Input, Price Volatility [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Fair value of warrants measurement inputs | 2.6227 | ||||||||||||||||||||||||||||||||||
Series F Preferred Stock [Member] | Maximum [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Warrant term | 6 months 10 days | ||||||||||||||||||||||||||||||||||
Series F Preferred Stock [Member] | Minimum [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Warrant term | 5 months 15 days | ||||||||||||||||||||||||||||||||||
Series G Convertible Preferred Shares [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Stated value per share | $ / shares | $ 5,000 | $ 5,000 | |||||||||||||||||||||||||||||||||
Common stock at a conversion price, per share | $ / shares | $ 0.50 | $ 0.50 | |||||||||||||||||||||||||||||||||
Preferred stock stated dividend rate | 8% | ||||||||||||||||||||||||||||||||||
Series G Preferred Stock [Member] | |||||||||||||||||||||||||||||||||||
Class of Stock [Line Items] | |||||||||||||||||||||||||||||||||||
Preferred stock shares issued | 0 | 0 |
Schedule of Share Based Payment
Schedule of Share Based Payments Arrangement, Option Activity (Details) | 6 Months Ended |
Jun. 30, 2022 $ / shares shares | |
Share-Based Payment Arrangement [Abstract] | |
Options Outstanding Beginning | shares | 384,050 |
Options outstanding, weighted average exercise price, beginning | $ / shares | $ 0.97 |
Options expired / forfeited | shares | (4,050) |
Options expired/forfeited, weighted average exercise price | $ / shares | $ 1.70 |
Options Outstanding Ending | shares | 380,000 |
Options outstanding, weighted average exercise price, ending | $ / shares | $ 0.98 |
Options Exercisable | shares | 380,000 |
Exercisable, weighted average exercise price | $ / shares | $ 0.98 |
Schedule of Share Based Payme_2
Schedule of Share Based Payment Arrangement, Option, Exercise Price Range (Details) | 6 Months Ended |
Jun. 30, 2022 $ / shares shares | |
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] | |
Number outstanding | shares | 380,000 |
Weighted- Average Remaining Contractual Life (Years) | 10 months 2 days |
Weighted average exercise price | $ 0.98 |
Number exercisable | shares | 380,000 |
Weighted average exercise price | $ 0.98 |
Range One [Member] | |
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] | |
Range of exercise prices | $ 0.98 |
Number outstanding | shares | 380,000 |
Weighted- Average Remaining Contractual Life (Years) | 10 months 2 days |
Weighted average exercise price | $ 0.98 |
Number exercisable | shares | 380,000 |
Weighted average exercise price | $ 0.98 |
Stock Incentive Plans (Details
Stock Incentive Plans (Details Narrative) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2022 | Jun. 30, 2021 | Jun. 30, 2022 | Jun. 30, 2021 | |
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||
Stock based compensation expenses | $ 0 | $ 0 | $ 0 | $ 0 |
Share-Based Payment Arrangement, Option [Member] | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||||
Share based compensation options outstanding exercisable | $ 0.07 |
Commitments and Contingencies (
Commitments and Contingencies (Details Narrative) - USD ($) | 1 Months Ended | ||||||
Aug. 24, 2021 | Jul. 28, 2021 | Oct. 30, 2019 | Feb. 16, 2022 | Nov. 17, 2021 | Jun. 30, 2022 | Dec. 31, 2021 | |
Loss Contingencies [Line Items] | |||||||
Warrants to purchase shares of common stock | 102,665,674 | 74,625,139 | |||||
Licensing Agreement MLR1019 [Member] | |||||||
Loss Contingencies [Line Items] | |||||||
Debt Instrument, Periodic Payment | $ 21,800,000 | ||||||
Gross sales percentage | 5% | ||||||
Option purchase percentage | 10% | ||||||
Royalty gross sales percentage | 2.50% | ||||||
Licensing Agreement MLR1019 [Member] | Minimum [Member] | |||||||
Loss Contingencies [Line Items] | |||||||
Gross sales percentage | 8% | ||||||
Licensing Agreement MLR1019 [Member] | Maximum [Member] | |||||||
Loss Contingencies [Line Items] | |||||||
Gross sales percentage | 12% | ||||||
Licensing Agreement MLR1023 [Member] | |||||||
Loss Contingencies [Line Items] | |||||||
Debt Instrument, Periodic Payment | $ 21,800,000 | ||||||
License agreement commitments description | if the Company failed to raise $4.0 million dollars within 120 days of the Effective Date then the License would immediately terminate unless, by 120 Days Adhera was in the process of completing transactions to complete the fundraising then an additional 30 Days would be provided to allow for the completion of the raise | the Company and Melior I, extending the requirement by the Company to raise $4.0 million dollars to June 16, 2022 | the Company’s timeline from 120 days to 180 days from the effective of the agreement for the Company to raise $4.0 million dollars unless, by 180 Days Adhera is in the process of completing transactions to complete the fundraising then an additional 30 Days shall be provided to allow for the completion of required fundraising | ||||
Series F Convertible Preferred Stock [Member] | |||||||
Loss Contingencies [Line Items] | |||||||
Number of shares repurchased | 20 | ||||||
Warrants to purchase shares of common stock | 150,000 | ||||||
Stock repurchase | $ 100,000 | ||||||
Value of warrants held | $ 100,000 |
Subsequent Events (Details Narr
Subsequent Events (Details Narrative) - Subsequent Event [Member] - Licensing agreement [Member] | Jul. 20, 2022 USD ($) |
Subsequent Event [Line Items] | |
Payment for licensing agreement | $ 136,921 |
Chief Scientific Officer [Member] | |
Subsequent Event [Line Items] | |
Capital raise in additional | $ 500,000 |